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Abstract 
An in vitro premalignant transformation model was established to investigate molecular 
changes during early lung carcinogenesis. hTERT/Cdk4-immortalized human bronchial 
epithelial cells (HBECs), harboring few genetic alterations, were exposed to  tobacco 
smoke carcinogens (benzo[a]pyrene, cigarette smoke condensate, or N-
methylnitrosourea) for 15 weeks. Transformed cell lines, defined by their ability to form 
colonies in soft agar, were used as models for molecular investigations, associated with 
changes in morphology and phenotype. This study shows for the first time that 
hTERT/Cdk4-immortalized HBECs have the ability to bioactivate the model-PAH, B[a]P  
sufficiently for transformation. Transformed HBECs provided suitable models for further 
investigations of molecular changes involved in bioactivation and transformation. 
Transformation was found to be largely associated with changes in cellular morphology 
from an epithelial to a mesenchymal-like shape. Transformed cells also gained an 
increased migration capability. These phenotypic changes may characterize an activation 
of the regulatory, developmental program termed epithelial-to-mesenchymal transition 
(EMT). This program is important during embryogenesis, but is also activated during 
cancer progression. Gene expression analyses revealed that the transformed cells also 
had reduced expression of the E-cadherin-gene (CDH1), and an increased expression of 
the N-cadherin-gene (CDH2). This cadherin switch is considered a molecular hallmark of 
EMT. These results indicate that EMT may also be activated during premalignant 
transformation.  
Steroid receptor signaling pathways have been hypothesized to be involved in lung 
carcinogenesis, possibly through an interaction with carcinogen metabolism. In this 
study, increased expression of androgen receptor, estrogen receptor β, and partly also 
estrogen receptor α was shown to be associated with transformation. This supports the 
hypothesis of a possible role of steroid receptor pathways during lung carcinogenesis. 
The forkhead box A (FOXA) transcription factors are involved in regulating steroid 
receptor activity and may form a link between steroid receptors and carcinogen 
metabolism. Little is known about these transcription factors in lung cancer. This study 
shows that the expression of FOXA1 and FOXA2 was significantly changed during 
premalignant transformation. FOXA2 has been found to act as a suppressor of EMT in 
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human lung cancer and in this study we observed both a downregulation of FOXA2 and 
the E-cadherin-gene (CDH1). In conclusion, steroid receptor pathways may be involved 
in carcinogen induced in vitro transformation of human lung cells, possibly through an 
interaction with carcinogen metabolism, but also through regulating EMT.  
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Abbreviations 
 
AHR    Aryl hydrocarbon receptor 
ANOVA  Analysis of variance 
ARNT      AHR nuclear transferase 
B[a]p       Benzo[a]pyrene 
BPDE       Benzo[a]pyrene diol epoxide 
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1  Introduction 
Cancer is the leading cause of death in economically developed countries and the 
second leading cause of death in developing countries (Jemal, Bray et al. 2011). The 
global burden of cancer continues to increase. This is largely because of the aging and 
growth of the world population, but the adoption of cancer causing behaviors such as 
smoking, physical inactivity, and westernized diets are also important factors.  
Lung cancer is the leading cause of cancer-related deaths worldwide (Parkin, Bray et al. 
2005). It was the most commonly diagnosed cancer, as well as the leading cause of 
cancer deaths in males in 2008.  Among females, it was the fourth most commonly 
diagnosed cancer and the second leading cause of cancer death. (Jemal, Bray et al. 2011)  
The relationship between smoking and lung cancer is thoroughly investigated and 
indicate that smoking is the predominant causal factor for lung cancer (Mattson, Pollack 
et al. 1987). Due to reductions in the frequency of smokers, both incidence and 
mortality rates among men have declined, but among women, mortality rates are still 
increasing (Jemal, Bray et al. 2011). This can mostly be explained by the fact that women 
started smoking later than men. An increase in tobacco consumption leads to an 
increase in the incidence of lung cancer a few decades later, but susceptibility factors 
among women have also been suggested. Epidemiological studies have indicated that 
women may be at a greater risk of smoking associated lung cancer, compared with men 
(Zang and Wynder 1996). Both epidemiological and molecular studies indicate that, for a 
given number of cigarettes smoked, women are at a higher risk of developing lung 
cancer (Kiyohara and Ohno 2010). Even though it appears that women might be more 
vulnerable to tobacco carcinogens, some studies indicate that men have a higher rate of 
fatal outcome of lung cancer (International Early lung cancer program Investigators et al. 
2006). 
The two major forms of lung cancer are non-small-cell lung cancer (NSCLC), which 
represents about 85 % of all lung cancers, and small-cell lung cancer (SCLC), accounting 
for the remaining 15 %. Nearly all patients (over 95%) diagnosed with SCLC are current, 
or ex-smokers. NSCLC can be divided into adenocarcinoma, squamous cell carcinoma 
and large cell carcinoma. Adenocarcinomas are the most common type of lung cancer 
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seen in non-smokers, but smoking has been increasingly associated as a cause in this 
disease (Youlden, Cramb et al. 2008). There has been a change in histology of lung 
cancer in which adenocarcinoma has now overtaken squamous cell carcinoma as the 
most common lung cancer type. This can at least partly be explained by the fact that 
over the period from 1959 to 1997, concentrations of the cigarette smoke carcinogen 
nicotine-derived nitrosamine ketone (NNK) increased, while that of benzo[a]pyrene 
(B[a]P) decreased. Exposure to NNK has been linked to adenocarcinoma, whereas 
exposure to B[a]P has been linked to squamous cell carcinoma (Hecht 1998). 
Despite improvements in survival for many other types of cancer, survival of lung cancer 
has remained relatively poor. Five years survival of cancers in the breast, colon, and 
prostate are four to six times longer than that observed for lung cancer (Table 1.1). The 
high mortality rate from lung cancer is partly due to late diagnosis. NSCLC is often 
diagnosed at an advanced stage and has poor prognosis. Also, the current lack of 
effective treatments for advanced lung cancer leads to the high mortality rate. It is 
assumed that a better understanding of the molecular changes during early lung 
carcinogenesis can contribute to earlier detection, which may decrease mortality rates. 
Increased knowledge may also help for the identification of susceptibility factors and the 
development of more targeted therapies and chemoprevention (Belinsky 2004; Damiani, 
Yingling et al. 2008). 
Table 1.1:  Five years survival for key cancers in the United States (Belinsky 2004). 
Cancer New cases Deaths 5-year survival (%)) 
Lung 171600 158900 14 
Colorectal 129400 56600 63 
Breast 176300 43700 85 
Prostate 179300 37000 93 
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1.1 Molecular biology of cancer  
Cancer is a broad group of diseases characterized by uncontrolled cell proliferation and 
tissue invasion. Cancer development is a complex, multistage process driven by the 
accumulation of genetic and epigenetic changes in genes controlling cell proliferation 
and tissue homeostasis. Uncontrolled cell proliferation may give the cells a selective 
growth advantage over adjacent cells.  This can lead to the formation of a neoplasm – a 
new autonomous growth - that proliferates without restraint.  As long as this neoplasm 
is not invasive it is defined as benign, but as it increases in size, so does the possibility of 
additional critical mutations and/or epigenetic changes in cancer genes. Eventually, the 
neoplasm can become malignant, invade adjacent tissues and spread into other parts of 
the body. This last stage of cancer development is termed metastasis (Hanahan and 
Weinberg 2000; Vogelstein and Kinzler 2004).  
There are three types of cancer genes: tumor suppressor genes, oncogenes and stability 
genes (Vogelstein and Kinzler 2004). Normally, cell proliferation is a strictly regulated 
process. Proto-oncongenes are normal genes involved in regulation of this process. 
Activation of proto-oncogenes into oncogenes, by mutations that render the gene 
constitutively active, often results in increased cell proliferation (Jones and Baylin 2007). 
Tumor-suppressor genes normally protect against development of neoplasms by 
regulating the progression through the cell cycle or by inducing apoptosis, when DNA is 
damaged. Inactivation of tumor suppressor genes results in reduction or loss of function, 
and may therefore promote cancer development. The third class of cancer genes - 
stability genes – are involved in DNA repair of mistakes made during replication or after 
exposure to carcinogens. Mutations in these genes accelerate the carcinogenic process 
by contributing to more genetic instability (Vogelstein and Kinzler 2004).  
Genetic changes are caused by mutations and have traditionally been considered as the 
major driving mechanism behind cancer development. Epigenetic changes have been 
given an increasing role and now it is assumed that genetic and epigenetic changes 
cooperate at all stages of cancer development. Epigenetics can be defined as heritable 
changes in gene expression that are not accompanied by changes in the DNA sequence 
(Jones and Baylin 2007). Cancer epigenetics involves mechanisms such as DNA-
methylation, histone modification, nucleosome positioning and noncoding RNAs, 
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specifically microRNA (mi-RNA) expression (Sharma, Kelly et al. 2010) (more on 
epigenetic mechanisms in cancer, see 1.8).  
Epigenetic changes are heritable, but also possibly reversible. The fact that epigenetic 
changes in theory may be reverted to their normal state by epigenetic therapy makes 
the field promising and therapeutically relevant.  
1.2 The physiological hallmarks of cancer 
Molecular changes in cancer genes all operate similarly at the physiological level: by 
giving the cell certain capabilities that increase cell proliferation and the ability to invade 
adjacent and distant tissues. Eight physiological capabilities have been described as the 
hallmarks of cancer (Hanahan and Weinberg 2000; Hanahan and Weinberg 2011). The 
transformation of normal cells into malignant cancers can be described as a progressive 
acquisition of an increasing number of these capabilities. The mechanisms behind the 
acquisition appear to be variable among cancer types. 
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Figure 1.1: The hallmark capabilities of cancer and one example of a mechanism behind the acquisition of each 
capability. Figure modified from (Hanahan and Weinberg 2011). 
Figure 1.1 shows the eight acquired hallmarks capabilities and an example of a 
mechanism behind. As mentioned, genetic and epigenetic changes that lead to 
activation of oncogenes or inactivation of tumor suppressor genes are the major 
mechanisms. Activation of the Ras oncogene is a frequent event in many cancers and 
lead to self-sufficiency in growth signals and uncontrolled cell proliferation.  In lung 
cancer, the K-Ras oncogene is mutated in 30-50% of adenocarcinomas (Subramanian 
and Govindan 2007). 
The p53 tumor suppressor gene has been regarded the “guardian of the genome” and is 
the most important inducer of apoptosis. Apoptosis (or programmed cell death) is an 
important response to DNA damage and various physiologic stresses. Apoptosis is 
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therefore an important tumor suppressing mechanism and resistance to apoptosis is a 
critical step in cancer development. p53 also plays an important role in DNA repair and 
cell cycle arrest. p53 is mutated in about half of all human cancer cancers and mutations 
involving p53 have been reported in 70% of SCLC patients and 50% of NSLC patients 
(Subramanian and Govindan 2007).  
In certain cells, such as stem cells, the enzymes telomerase enzyme hinders the 
progressive shortening of the ends of chromosomes that otherwise take place during 
cell replication. This is done by maintaining or extending telomeres. Most normal cell 
lineages in the body have a finite replicative potential and lack telomerase activity. 
Replicative cell senescence is also a tumor suppressing mechanism because it 
counteracts the accumulation of mutations. Limitless replicative potential is a 
phenotype that is probably acquired during transformation, and activation of the 
telomerase enzyme is one suggested mechanism (Hanahan and Weinberg 2000). 
In the last stage of cancer development, metastasis, cancer cells can escape the primary 
neoplasm and spread to distant tissues. A developmental regulatory program termed 
“Epithelial-mesenchymal transition” (EMT) is often activated during this malignant 
transformation. By activating this program, cells become able to invade and spread to 
distant tissue to form secondary tumors. One suggested mechanism behind is the 
inactivation of E-cadherin which is a molecule that form adherence junctions and is 
important for assembling tissue (For more information on EMT, see 1.7). 
1.3 Chemical carcinogenesis 
A carcinogen is any chemical, physical or viral agent that causes cancer or increases the 
risk of developing cancer. Exposure to carcinogens, endogenous or exogenous, induces 
the genetic and epigenetic changes that may lead to cancer development. Operationally, 
the multistep carcinogenesis can be divided into three stages, defined as initiation, 
promotion and progression.  
15 
 
 
Figure 1.2: Three stage model of carcinogenesis. Figure modified from (Harris 1991). 
The first stage, tumor initiation, involves exposure of normal cells to a genotoxic 
carcinogen that interact physically with DNA to induce a mutation. The initiated cell 
may, for instance, be less responsive to negative growth factors and inducers of 
programmed cell death. The initiated cell can have many fates: it can remain in a 
nondividing state, be deleted through apoptosis, or undergo cell division. If the initiated 
cell divides, without damage to DNA being repaired, the genetic change is fixed. The 
next stage, tumor promotion, involves proliferation of the initiated cells to a greater 
extent than normal, leading to development of a neoplasm. Nongenotoxic carcinogens, 
called tumor promoters, act at the promotion stage by inducing increased cell 
proliferation without interacting with the DNA. The promotion stage is therefore 
reversible. As the neoplasm increases in size, there is an increasing probability of 
additional genetic damage. This can lead to more genetic and epigenetic changes in 
cancer genes and the development of malignant neoplasm and metastatic cancer. This 
final stage of carcinogenesis is called progression and is characterized by genomic 
instability manifested as an abnormal number and structure of chromosomes, gene 
amplification, and altered gene expression (Harris 1991)  
This simplified three-stage carcinogenesis model demonstrates that carcinogens can 
play different roles as tumor initiators and tumor promoters. Carcinogens that can act 
both as tumor initiators (genotoxic) and promoters (nongenotoxic), and thereby induce 
cancer through all three stages of carcinogenesis are called complete carcinogens. This 
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three-stage model also demonstrates that the carcinogen induced transformation of 
normal cells into cancer cells is a stochastic, complex and time consuming process. 
1.4 Chemicals in cigarette smoke 
Approximately 4000 chemicals have been identified in cigarette smoke and more than 
60 of these chemicals have been evaluated by the International Agency for Research on 
Cancer (IARC) to show sufficient evidence for carcinogenicity in either animals or 
humans. Chemicals are classified in IARC group 1 when both human and animal data are 
strong, in group 2A when human epidemiological data are suggestive and animal data 
strong, and when human epidemiological data are weak but animal data positive, they 
are classified in group 2B (see Table 1.2)  
Experimentally, vapor-phase components of the smoke can be separated from the 
particulate phase by a glass fiber filter. The vapor-phase consists of nitrogen, oxygen, 
and carbon dioxide. The particulate phase contains many chemicals including PAH, N-
nitrosamines, aromatic amines and metals. Cigarette smoke condensate can be 
prepared by trapping non- volatile (particulate phase constituents) in cold-traps. 
Cigarette smoke condensate (CSC) reproducibly causes tumors when applied to mouse 
skin and implanted in rodent lung. In addition to containing genotoxic compounds, CSC 
has tumor promoting ability (Pfeifer, Denissenko et al. 2002). 
Available data indicate that PAH and NNK are important carcinogens in cigarette smoke 
most likely to be involved in lung cancer initiation in smokers. It should be noted that 
some of the strongest carcinogens such as PAH, and NNK are present in lower 
concentrations and that weaker carcinogens, such as formaldehyde, are present in 
higher concentrations. PAH are strong locally acting carcinogens and their ability to form 
tumors has been convincingly established. The model-PAH, B[a]P, is a complete 
carcinogen. NNK are strong systemic lung carcinogens that primarily produce 
adenocarcinoma.  
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Table 1.2: The major groups of tobacco smoke carcinogens and the most important within each group. Modified 
from IARC monograph 83 (2004)  
Agent Notable chemicals IARC group Amount in 
mainstream 
cigarettes smoke 
Polycyclic aromatic 
hydrocarbons (PAH) 
 (B[a]P 1 8.5- 11.6 ng 
N-Nitrosamines NNK 
N-Nitrosonornicotine 
(NNN) 
1 
1 
110- 133 ng 
154- 196 ng 
Aromatic amines 4-Aminobiphenyl 
2-Naphtylamine 
1 
1 
 2- 5 ng 
1-22 ng 
Aldehydes Formaldehyde 
Acetaldehyde 
1 
2B 
10.3-25 ug 
770-864 ug 
Volatile hydrocarbons 1,3-butadiene 
Benzene 
2A 
1 
20-40 ug 
12-50 ug 
Miscellaneous 
organic compounds 
Ethylene oxide 
Vinyl chloride 
1 
1 
11-15 ug 
Metals Cadmium 
Arsenic 
1 
1 
41-62 ng 
40-120 ng 
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1.5 Carcinogen metabolism 
When the body is exposed to foreign chemicals, it will try to excrete them by converting 
them to a more soluble form. The metabolism of foreign compounds is performed by 
biotransformation enzymes and can be divided into three phases: In phase I 
(bioactivation), enzymes such as Cytochrome P450 (CYP) introduce reactive or polar 
groups into the foreign compound to increase water solubility. In phase II 
(detoxification), these modified compounds are conjugated to polar compounds, which 
are highly soluble in water. These conjugation-reactions are catalyzed by enzymes such 
as glutathione S-transferase, glucuronosyl-transferase and sulfo-transferase. Finally, in 
phase III, the conjugated compounds may be further processed and transported out of 
the cell (Zhang, Wang et al. 2006). 
Some of the intermediates formed by the phase l enzymes (bioactivation) are 
electrophillic and can react with DNA. This can result in the formation of DNA adducts 
and mutations. Carcinogens can be divided into direct-acting which can induce damage 
to the DNA directly, and indirect-acting carcinogens that needs to be bioactivated before 
they can induce DNA damage. Carcinogen bioactivation and the resulting formation of 
ultimate carcinogens is an inadvertent outcome of the detoxification process.  
The human lung is the major target of all inhaled carcinogens, and biotransformation 
enzymes play a dominant role in the toxicological effect of these carcinogens. The 
cytochrome P450 family is a large class of enzymes that fulfill many biological functions 
such as biosynthesis of steroid hormones and biotransformation of chemicals (Zhu 
2010). CYP1A1 and CYP1B1 are some of the major isoforms of the CYP enzymes 
expressed in lung tissue and they play a major role in the bioactivation of B[a]P in 
human lung cell lines (Uppstad, Ovrebo et al. 2010). 
The metabolism of B[a]P is extensively studied and has served as a model for 
biotransformation of PAHs. PAHs are important constituents in cigarette smoke, but are 
also present in broiled foods, soot, tars and automobile exhaust. Figure 1.4 illustrates 
that B[a]P metabolism can follow a detoxifying pathway leading to conjugates that can 
be excreted, and a bioactivation pathway leading to the formation of the ultimate 
carcinogen benzo[a]pyrene-diol-epoxide (BPDE)(Sagredo, Ovrebo et al. 2006). 
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Figure 1.3: B[a]P metabolism. Vertical pathway shows detoxification, while horizontal pathway lead to activation 
and the possible formation of adducts. Figure modified from (Sagredo, Ovrebo et al. 2006). 
BPDE is highly reactive and have the ability to form covalent bonds with bases in the 
DNA molecule, resulting in DNA adducts. Cellular repair systems, such as nucleotide 
excision repair, eliminates DNA adducts. DNA repair is an important function for 
maintaining the integrity of the genome and if the adducts escape repair, mutations may 
arise. The major adduct of BPDE produces GC-TA mutations (Pfeifer, Denissenko et al. 
2002). Mutations caused by BPDE adducts in vitro are the same that those found in the 
p53 gene in tumors from lung cancers. These mutations thereby establish a molecular 
link between exposure and a specific type of cancer. 
Many biotransformation enzymes present in the human lung are inducible by exposure 
to carcinogens or other foreign compounds. The purpose of enzyme induction is an 
accelerated metabolism and excretion of the chemicals being exposed. B[a]P and other 
PAHs are  primarily bioactivated by CYP1A1 (Uppstad, Ovrebo et al. 2010) which is 
regulated by the Aryl hydrocarbon receptor (AHR) (Zhu 2010). AHR is a ligand-activated 
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transcription factor that functions as an intracellular mediator in xenobiotic pathways. 
AHR also plays an important role in the regulation of cell growth and differentiation. 
B[a]P act as a ligand and bind to the AHR in the cytoplasm (see Fig. 1.4). The liganded 
AHR is then translocated to the nucleus where it forms a heterodimer with the AHR-
nuclear translocator (ARNT). The AHR/ARNT heterodimer recognize and binds to 
xenobiotic responsive element (XRE) sequences located in the promoter region of 
several genes such as CYP1A1 and glutathione S-transferases.  The binding results in 
transcriptional activation of the genes and induction of phases I and II metabolizing 
enzymes as well as phase III transporter proteins. (Sagredo, Ovrebo et al. 2006; Zhu 
2010)  
 
 
Figure 1.4: An inducer chemical, such as B[a]P bind to AHR.  This lead to transcription of several genes, including 
CYP1A1, which is necessary for the metabolism of B[a]P. Figure modified from (Zhu 2010). 
The balance between bioactivation and detoxification varies among individuals and is 
considered to be important for cancer susceptibility. The level of different 
biotransformation enzymes is one determining factor and then also the efficiency of 
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enzyme induction by AHR.  A reduction or loss of B[a]P carcinogenicity is observed in 
mice lacking the Ahr (Shimizu, Nakatsuru et al. 2000; Sagredo, Mollerup et al. 2009). 
Upregulation of CYP1A1 through the AHR and is assumed to increase B[a]P 
carcinogenicity and susceptibility. Higher frequencies of GC-TA transversions in the p53 
gene in lung tumors of smoking female lung cancer patient, compared to males, have 
been observed (Kure, Ryberg et al. 1996). In addition, female lung cancer patients have 
been found to have a higher level of both CYP1A1 expression and PAH-DNA adduct 
levels, compared to men (Mollerup, Ryberg et al. 1999). The level of DNA adducts may 
be a risk factor for the development of cancer (Veglia, Matullo et al. 2003). Higher 
frequencies of GC-TA transversions in the p53 gene, which are signatures of PAH-
exposure, have also been reported in lung tumors of smoking female lung cancer 
patients. These findings may indicate higher susceptibility to tobacco smoke carcinogens 
among females. 
1.6 Steroid receptor pathways  
Because there are indications of sex differences in susceptibility to tobacco smoke 
carcinogens, steroid receptors and circulating hormones have been suggested to play a 
role in lung carcinogenesis. One mechanism may be that circulating hormones interact 
with receptors in the lung to modulate carcinogen metabolizing enzymes.  
Steroids have been implicated as a casual factor in many cancers, such as estrogen and 
breast cancer. It is well known that estrogen can stimulate cell signaling and 
proliferation in the breast via Estrogen receptor (ER) pathways and ER independent 
pathways (Yager and Davidson 2006). In liver cancer, androgens have been suggested as 
a reason for the sex differences observed in this disease (Li, Tuteja et al. 2012). 
Androgens have also been found to enhance DNA damage and oxidative stress in liver 
cancer (Ma et al.,2008). The adult lung is an AR target tissue and there are indications 
that AR plays a role also in lung cancer biology.  
Estrogen regulated gene expression is mediated by the action of two members of the 
nuclear receptor family, ERα and ERβ. Both normal human lung tissue and lung tumor 
cell lines have been found to express ERα and ERβ (Mollerup, Jorgensen et al. 2002). A 
cross-talk between ER and AHR has been observed (Thomsen, Wang et al. 1994; Caruso, 
22 
 
Laird et al. 1999). This may suggest that Estrogen receptor pathways may interact with 
carcinogen metabolism. Other Studies show that the continued presence of estrogen is 
required to maintain high levels of AHR expression and thereby the inducibility of 
CYP1A1 and CYP1B1, in breast cancer cells (Spink, Katz et al. 2003). A similar interaction 
of AHR and ER in lung carcinogenesis has been suggested and has been hypothesized to 
at least partly explain sex differences in tobacco carcinogen susceptibility, but this is 
conflicting (Haugen 2002). One recent study did not support a role of ER in regulation of 
PAH bioactivation in the human lung (Berge, Mollerup et al. 2004). Other studies 
indicate that a downregulation of ERα and ERβ, by using siRNA, can affect CYP1A1 gene 
expression (Uppstad, Mollerup, unpublished data). 
Recently, there has been an increasing focus on genes involved in the activity and 
regulation of steroid receptors activity. The vertebrate forkhead box A (FOXA) gene 
family of transcription factors are involved in regulation of steroid receptor pathways. 
They have also been found to be involved in cancer development. The FOXA gene family 
consists of three members: FOXA1, FOXA2 and FOXA3 which are encoded by different 
genes. These are tissue specific transcription factors important during development and 
differentiation (Lin, Miller et al. 2002. FOXA1 is important in the regulation of AR and ER 
activity and several studies indicate that this transcription factor plays a role in several 
cancer types (Augello, Hickey et al. 2011; Bernardo and Keri 2012). Genome wide 
location analyses have also revealed that FOXA1 and ERα and AR bind to cis-regulatory 
elements in their target genes in human breast and prostate cancer cell lines, 
respectively, and that the recruitment of ERα or AR to their targets, depends on FOXA1. 
FOXA1 and FOXA2 are thought to be important for sexual dimorphism of in liver  cancer, 
where estrogen has a protective effect, and androgen a deleterious effect (Kongsuwan, 
Knox et al.) In this study, it was also found that the genes regulated by the sex hormone 
receptors and FOXA factors, clustered in the pathways controlling carcinogen 
metabolism. Tumor growth was also shown to be strongly dependent on Foxa1/2. Large 
tumors were found in female Foxa1/2 deficient mouse livers, while tumor growth in 
male mutants was reduced (Li, Tuteja et al. 2012). 
In one study, FOXA1 was amplified and overexpressed in lung adenocarcinoma (Lin, 
Miller et al. 2002).  FOXA2, on the contrary, has recently been found to be 
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downregulated in lung cancer (Basseres, D'Alò et al.). Little is known about the role of 
these transcription factors is lung cancer. There are indications that these factors may 
be involved in regulating carcinogen metabolism (Li, Tuteja et al. 2012), and a recent 
study also suggest they are involved in regulating EMT (Tang, Shu et al. 2011). 
GREB1 (growth regulation by estrogen in breast cancer 1), is critically involved in the 
estrogen induced growth of breast cancer cells. GREB1 is characterized as an ERα target 
gene, with three estrogen response elements (ERE) located on its promoter (Chand, 
Wijayakumara et al. 2012). Little is known about GREB1 in lung cancer, but in addition to 
the FOXA transcription factors, its expression may be indicative of the activity of steroid 
receptors and may also be involved in lung cancer. 
1.7 Epithelial-to-mesenchymal transition (EMT) 
Epithelial-to-mesenchymal transition (EMT) is a developmental program that is 
important in embryogenesis and wound-healing. Activation of this program has been 
implicated as an important step in cancer invasion and metastasis (Mani, Guo et al. 
2008). EMT is characterized by loss of epithelial markers, gain of mesenchymal markers 
and changes in cellular morphology and phenotype. Through activation of this program, 
cells acquire an increased ability to migrate and invade other tissues, which are 
important characteristics during metastasis (Fig 1.5).  
 
Figure 1.5: Activation of EMT during cancer invasion and metastasis. Figure modified from (Kalluri and Weinberg 
2009) 
As mentioned earlier, one of the key characteristics of EMT is inactivation of E-cadherin. 
E-cadherin form adherence junctions with adjacent epithelial cells and thereby helps 
assemble epithelial tissue. The expression of N-cadherin, on the contrary, is upregulated 
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during EMT. N-cadherin is normally expressed in migrating neurons and mesenchymal 
cells during embryogenesis. Downregulation of E-cadherin and upregulation of N-
cadherin, often referred to as the cadherin switch, is therefore considered a molecular 
hallmark of EMT (Kalluri and Weinberg 2009). 
 
 
Figure 1.6: Some of the epithelial and mesenchymal markers commonly associated with EMT (Kalluri and Weinberg 
2009). 
Recent in vitro studies indicate that EMT also can be activated in early stages of 
carcinogenesis. EMT in vitro models have been established in both lung and prostate 
cancer cells. (Ke, Qu et al. 2008). These models allow a clearer identification of the 
molecular mechanisms of EMT, associated with altered morphology. Recent studies 
indicate that EMT can be activated in early stages of lung carcinogenesis and that several 
epigenetic mechanisms are involved. Exposure of human bronchial epithelial cells to 
tobacco carcinogens induced the EMT- program in a premalignant in vitro model. EMT 
induction was associated with tumor supressive miRNA silencing (Tellez, Juri et al. 2011). 
Both chromatin remodeling and DNA methylation was involved in the sustained 
silencing of these miRNAs. One recent study also observed a link between EMT and 
FOXA1/2 in pancreatic cancer. In this study FOXA1/2 expression showed a positive 
regulation of E-cadherin and maintenance of the epithelial phenotype (Song, 
Washington et al. 2012) 
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1.8 Epigenetic mechanisms 
Among the epigenetic mechanisms involved in cancer, changes in DNA methylation and 
miRNA expression will be discussed here. DNA methylation is important in regulating 
many cellular processes and in most cases results in silencing of genes. DNA methylation 
primarily occurs by the covalent modification of the cytosine bases in CpG dinucleotides. 
CpG sites are not evenly distributed in the genome.  Instead, they are concentrated in 
CpG rich regions called CpG islands. These CPG Islands are often located in the promoter 
region of protein coding genes. Their methylation is associated with gene silencing 
(Sharma, Kelly et al. 2010). In mammalian cells, DNA methylation is carried out by two 
general classes of enzymatic activities: Maintenance methylation and de novo 
methylation. The enzymes that are responsible for these activities are called DNA 
methyltransferase (DNMT)(Chuang and Jones 2007).  As mentioned previously, 
inactivation of tumor suppressor genes is an important mechanism behind cancer 
development and DNA hypermethylation of tumor suppressor genes occurs in many 
types of cancer. In lung cancer, more than 60 genes have been identified as 
epigenetically silenced in lung tumors (Belinsky 2004). In one recent study gene 
promoter hypermethylation mediated by DNMT1 was associated with transformation of 
immortalized bronchial epithelial cells (Damiani, Yingling et al. 2008). 
MicroRNAs are small RNAs (~22 nt) that regulate gene expression by posttranscriptional 
silencing (Bartel 2009). Sequence-specific base pairing of miRNA with 3` untranslated 
region (3`-UTR) of mRNA result in mRNA degradation or inhibition of translation 
(Sharma, Kelly et al. 2010). miRNA seem to have a modest effect on gene regulation with 
less than 30 % downregulation of most of its targets, but some miRNAs can result in 50-
80 % reduction of expression of its mRNA targets (Baek, Villén et al. 2008).  Each miRNA 
can target several mRNAs, and conversely, each mRNA can be targeted by several 
miRNAs (Enright, John et al. 2003). It has been suggested that miRNA act through fine 
tuning rather than switching of its targets.  miRNA control many biological processes 
including cell proliferation, apoptosis and differentiation, which also suggest that they 
may play a role as tumor suppressor genes or oncogenes. Generally, the expression of 
miRNAs is found to be downregulated in cancer cells, but a few miRNAs have been 
found to be upregulated (Lynam-Lennon, Maher et al. 2009; Martello, Rosato et al. 2010). 
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MiR-21 is one of the most studied miRNAs in cancers. MiR-21 is overexpressed in the most solid 
tumors, promoting progression and metastasis (Tian, Tu et al. 2012). 
1.9 Human bronchial epithelial cell lines for in vitro studies. 
Primary bronchial epithelial cells have a finite replicative potential. This is partly due to 
lack of telomerase activity and shortening of telomeres. For the use in in vitro studies, 
cell lines are therefore immortalized. Immortality can be accomplished by introduction 
of oncogenes or silencing of tumor suppressor genes. One way to induce immortality is 
through viral-mediated induction of viral onco-proteins, but such attempts to establish 
long-term replicating cultures have generated variants which may become 
spontaneously transformed (or malignant) after many passages.  These cells are often 
genomically unstable and the p53 gene has often been inactivated (Gazdar, Gao et al. 
2010). Human bronchial epithelial cell lines with viral-mediated immortalization may 
therefore be more appropriate in studies of later stages of lung carcinogenesis. Recently, 
human bronchial epitheilial cells have been immortalized by the insertion of the 
telomerase (hTERT) catalytic subunit and the cyclin-dependent kinase 4 (CDK4) (Ramirez, 
Sheridan et al. 2004). These HBECs have an intact p53 checkpoint and are genomically 
stable. They may therefore be considered a suitable model to study early premalignant 
changes in lung carcinogenesis. 
An In vitro model may be helpful for the identification of premalignant molecular 
changes in order to acquire increased knowledge of early steps in lung carcinogenesis. 
Such models have been restricted by the immortalized cell lines available. An in vitro 
transformation model, using HBEC-KT cells, has recently been developed (Damiani, 
Yingling et al. 2008).  HBECs do not form colonies in soft agar or tumors in nude mice at 
the starting point. In this model, cells that acquire the ability of anchorage independent 
growth, and thus form colonies in soft agar are defined as transformed. Transformed cell 
lines can then be used to investigate molecular changes associated with transformation. 
1.10 Aim of the study 
The aim of this study was to establish an in vitro transformation model for studies of 
molecular changes during premalignant transformation. Steroid receptor pathways have 
been hypothesized to be involved in carcinogen induced transformation. Because we 
have an interest in steroid receptor pathways in relation to carcinogen metabolism, this 
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in vitro transformation model would include exposure of HBECs to indirect-acting 
carcinogens, such as B[a]P, in order to test the cells capacity to bioactivate this 
carcinogen sufficiently for transformation. We also wanted to test other, including 
direct-acting, tobacco smoke carcinogens.  
Further, if HBECs were transformed, the aim was to establish transformed cell lines to be 
used to investigate molecular and morphological changes resulting from bioactivation 
and carcinogen induced transformation. Transformed cell lines would be used to 
investigate if changes in gene expression among steroid receptor pathway members, 
including the FOXA genes, were associated with transformation. Also, both cellular and 
molecular changes associated with EMT would be investigated to determine if EMT 
could be involved in carcinogen induced transformation. Finally, epigenetic mechanisms 
are highly involved in carcinogenesis and also in the regulation of steroid receptor 
pathways and EMT. Therefore, we also wanted to test for epigenetic changes in 
transformed cell lines. 
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2 Materials and method 
An in vitro transformation model of human lung epithelial cells was used to study early 
steps of chemically induced lung carcinogenesis. An overview of the cellular and 
molecular analysis that were performed during and after the transformation assay, are 
shown in Figure 2.1.  
 
Figure 2.1: Outline of methods used. 
2.1  General cell work and optimization. 
All cell work was performed under sterile conditions in OAS LAF benches with gas 
burner, ventilation and with the use of plastic pipettes (Fisher Scientific). Protocols for 
general cell work, such as passaging of cells and freezing of cells for storage, are 
described in Appendix A. Cells were grown in 100 mm dishes, 96 well-, 6 well- or 24 well-
plates (NUNC, Nunclon surface sterile) and passaged when 80 % confluent. The HBECs 
were grown on collagen coated dishes (see Appendix A). 
2.1.1  Cell lines and culture conditions 
Cells were taken up from STAMIs liquid nitrogen cell bank and cultured at 37 °C in a 
humidified 5 % CO₂ atmosphere (Thermo Forma incubator). hTERT/Cdk4-immortalized 
bronchial epithelial cells (HBEC) were used for the transformation assay. HBEC were 
grown in LHC-9 medium (Gibco, Invitrogen, cat.no. 12680-013) added 1% PS and 10% 
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FBS (see Appendix G). The characteristics of the three different HBEC cell lines that were 
available are outlined in Table 2.1. The tumor cell lines A549 and A427 were used for 
optimization of soft agar assay. A427 cells were grown in RPMI 1640 medium (Gibco, 
Invitrogen ref. 21875- 034) and A549 cells in DMEM/F-12 (Gibco, Invitrogen, ref: 21331-
020) both added 1% PS and 10% FBS. 
Table 2.1: Properties of the HBEC cell lines at STAMIs cell bank 
Cell line Age of donor Sex of donor Diagnosis 
HBEC-2KT 68 Male NSCLC 
HBEC3-KT 65 female No cancer 
HBEC-12KT 55 female NSCLC 
 
2.1.2  Seeding of cells for experiments 
The following is a description of the general procedure for seeding of cells for 
experiments. This procedure, including materials and reagents, will not be repeated for 
each experiment, specific details only. The volumes of the different solutions were 
adapted to the size of the dishes used. This description is for 100 mm dishes. 
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Materials  Reagents  
Microcentrifuge tubes. 0.5 ml and 1.5 ml  
(Trefflab)  
Suitable growth medium  
 Light microscope  
(Nikon Diaphoto)  
DNAse , from bovine pancreas, 4 mg/ml  
(Sigma)  
Centrifuge tubes  
(Falcon) 
Trypsin , 0.05 % in PBS  
(Gibco, Invitrogen)  
Cellteller, Countess-Automated Cell-Counter  
(Invitrogen)  
Trypan blue stain 0.4%  
(Invitrogen)  
Cell Counting chamber slides  
(Invitrogen)  
 
Centrifuge  
(Eppendorf 5702)  
 
 
Protocol 
1. 80 % confluent cultures were the starting point for experiments. The medium 
over the cells was removed. 
2. The dish was washed twice with 8 ml PBS. 
3. 1 ml trypsin solution was added, and the cells were incubated at 37 °C until they 
had loosened from the dish, which was visible in the light microscope. 
4. 5 ml growth medium was added the cell-suspension was transferred to a 
centrifugation tube and centrifuged for 4 minutes at 1000 rpm. 
5. The supernatant was removed and the pellet was re-suspended in 5 ml growth 
medium. Certain cell lines (A427, A459) required the addition of 20μl DNAase to 
the pellet to obtain single-cell suspension. 
6. Cells were counted using a Countess automated cell counter. 10 μl cell 
suspension was mixed with 10 μl trypan blue stain in a 0.5 ml microcentrifuge 
tube. 10 μl of this mix was then pipetted onto Cell Counting chamber slides.  
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7. The cell suspension was mixed with new growth medium to obtain the desired 
cell density. Countess automated cell-counter calculated this. Cells were seeded 
on 6 or 96-well plates. 
2.1.3  Cytotoxicity test with CellTiter Blue assay 
The reagent CellTiter-Blue (CTB) uses the indicator dye resazurin to measure the 
metabolic capacity of cells, an indicator of cell number or cell viability. Viable cells 
reduce resazurin into resorufin, which is highly fluorescent and emits fluorescence at 
590 nm. The fluorescence produced is proportional to the number of viable cells. The 
CTB assay was used to test toxicity of B[a]P to HBEC cell lines.  Different quantities of 
cells were seeded on a 96-well plate and fluorescence was measured to show this 
relationship (see Appendix B). 
 
Materials 
 
Reagents 
 
Modulus microplate reader  
(Turner Biosystems) 
 B[a]p 
(Sigma B-1760-1G) 
96-well plates  
(NUNC, Nunclon surface sterile) 
99.99 % DMSO  
(Kock Licht 2228-00) 
 CellTiter Blue-reagent, CTB  
(Promega) 
Protocol 
1. Day one, HBEC-2KT and HBEC-12KT were seeded out, 800 cells/well on 96-well 
plates, and incubated for 24 hours.  
2. Day two, Cells were exposed to 0.33, 1, 3 and 10 μM B[a]P in LHC-9 medium. 
Solutions of 0.33, 1, 3 and 10 mM B[a]P were made in DMSO. These were diluted 
1:1000 in LHC-9 medium, resulting in a final concentration of 0.1 % DMSO. 
Medium containing DMSO only was used as control.   
3. Day four, the medium over the cells was removed and step 2 was repeated. 
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4. On day seven, the medium over the cells was removed. The cells were washed 
twice with PBS. CTB reagent was added to each well (15 μl CTB/100μl medium). 
CTB was also added to empty wells to make a blind control. The plates were then 
left for two hours at 37 °C in the cell incubator. 
5. Fluorescence was measured at 560/590nm in the Modulus microplate reader. 
6. Fluorescense of the blind control was subtracted from fluorescence of the cells.  
2.1.4 Cytotoxicity test with Countess- Automated Cell-Counter 
Countess- Automated Cell- Counter measures the number and fraction of live cells. This 
can be used to measure cytotoxicity. HBEC-2KT and 12-KT were exposed to B[a]P, CSC 
and DMSO. Several cell counting tests with B[a]P and CSC were performed and different 
protocols were used, including different exposure frequencies.  Exposure duration 
varied from four hours until three days. The following is a description of the protocol for 
one week exposure. 
Protocol 
1. Day one, HBEC-2KT and HBEC-12KT were seeded, 10 000 cells/well on 6-well 
plates and incubated for 24 hours.  
2. Day two, cells were exposed to 0.33, 1, 3 and 10 μM B[a]P in LHC-9 medium and 
1.11, 3.33, 10 and 30 μg/ml CSC in LHC-9 medium. Both agent were diluted in 
DMSO (0,1 % final concentration) and DMSO only was used as a control. 
3. Day four, the medium over the cells was removed and step 2 was repeated. 
4. On day seven, the medium was removed and 1 ml trypsin was added. The plates 
were incubated until they had loosened from the dish, visible in light microscope. 
5. Cells were counted using the automated cell counter. The number of live cells 
per well and the fraction live/dead was registered. 
2.2  Transformation assay – 15 weeks chemical exposure  
HBEC-2KT and HBEC-12KT were exposed to different tobacco chemicals weekly for 15 
weeks. Each cell line was subjected to 6 different exposures weekly (see Table 2.2). Each 
exposure experiment was performed in 4 parallels.  
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Figure 2.2: Outline of cellular assays performed during and after the transformation assay. All stages were 
inspected in the light microscope for morphological changes. 
 
Table 2.2: Table shows the different carcinogen doses and exposure durations for each cell line.  
 MNU B[a]P CSC DMSO 
(Control) 
HBEC-2KT 1 mM   
1 hour 
Low dose  
0.33 μM , 3 days 
Low dose  
1 µg/ml, 3 days 
0.1 % 
3 days 
  High dose 
1 μM, 3 days 
High dose 
3 µg/ml, 3 days 
 
HBEC-12KT 0.5 mM       
1 hour 
Low dose  
0.33 μM, 3 days 
Low dose 
1 µg/ml, 3 days 
0.1 % 
3 days 
  High dose 
1 μM, 3 days 
High dose 
3 µg/ml, 3 days 
 
 
At several stages during the exposure period, cells were taken out and seeded on new 6-
well plates for various molecular analyses. After grown to confluence and washing three 
times in PBS, dishes for RNA analysis were put in -80°C freezer, while dishes for DNA and 
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protein analysis were put in the -20°C freezer until further processing (to be carried out 
in the lab after this master project)  
Protocol 
1. Day one, cells were seeded in 1.5 ml medium on 6-well plates and incubated for 
24 hours. HBEC-2KT was seeded at 10 000 cells/well and HBEC-12KT at 20 000 
cells/well. 
7. Day two, exposures were initiated. Solutions of 0.33 and 1 mM B[a]P, 1 and 3  
mg/ml CSC and 1 M MNU were made in DMSO. These were diluted 1:1000 in 
LHC-9 medium, resulting in a final concentration of 0.1 % DMSO. Medium 
containing DMSO only was used as control.   
2. After one hour MNU was removed from the cells. The dishes were washed in PBS 
and 2 ml fresh LHC-9 medium/dish was added. 
3. Day five, B[a]P and CSC was removed from the cells. The dishes were washed in 
PBS and 2 ml fresh medium was added. In addition, the medium over the MNU 
exposed cells was changed. 
4. Day eight (day one in the next week), the cells were passaged, counted, and 
seeded on new 6-well plates (see 2.1.2) at cell densities described above.  
5. The procedure was repeated for 15 weeks. 
2.3  Soft agar assay 
The soft agar assay is an in vitro cellular transformation detection assay. In this study, it 
was used to measure cell transformation induced by carcinogens. This transformation is 
associated with certain phenotypic changes, such as loss anchorage independence. 
Anchorage independence gives the cells an ability to form colonies in soft agar.  
Anchorage independent growth, and thereby colony formation in soft agar, is a typical 
trait for tumor cell lines. To optimize the soft agar protocol, the human lung tumor cell 
lines A549 and A427, which have previously been shown to form colonies in soft agar, 
were used.  
The soft agar is composed of a base-layer and a top-layer. The base-layer is made first. 
After solidifying, a top-layer containing a lower concentration of agar and a specified 
number of cells is added. Each of the parallels from the exposure regimen was seeded 
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out on two 6-well plates. While working, the agar solutions were kept in a water bath at 
45 °C. It was important to work fast so that the agar solutions did not gel before they 
were supposed to. The agar was not mixed with cells before the temperature was under 
37 °C.
For the HBEC-2KT and 12-KT cell lines, cells were taken out from the exposure regimen 
after 9, 12 and 15 week of chemical exposure and seeded in soft agar to test for 
transformation. 
Protocol
1. 1 g Difco agar noble (BD, ref.214220) was mixed with 33.3 ml PBS to obtain a 3 % 
agar stock solution which heated on a warming plate until boiling. 
2. This agar stock solution was autoclaved on the program for agar solutions (Systec 
DX-90). 
3. The 3 % agar stock solution was mixed with growth medium to obtain 0.7 % base 
agar. 
4. 1.5 ml 7 % base agar was added each well in 6-well plates and allowed to gel at 4 
°C.  
5. Cells were trypsinized and counted and the cell suspension was diluted in 
medium to obtain 2000 cells/ml.  
6. This cell suspension was mixed with an equal volume 0.7 % agar solution to 
obtain 0.35 % top agar solution with 1000 cells/ml.  
7. 1 ml of this cell-containing top-agar was added on top of a base-agar-containing 
well. 
8. The plates were immediately put at 4 °C and kept there for 30 minutes to allow 
for the top-agar to gel. This was followed by incubation at 37 °C for at least 3 
weeks.  
9. 500 µL fresh medium was added after two days. This medium was changed once 
a week. 
2.3.1  Crystal violet staining of cells and colony counting 
Plates were inspected in the light microscope for appearance of colonies daily. To 
visualize and count colonies in soft agar, staining with Crystal violet was used. When 
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dissolved in water, Crystal violet has a blue violet color. Crystal violet stains cell walls, so 
that cell colonies will be clearly visible. 
1. Crystal violet (Sigma) was dissolved in autoclaved water in two steps. First, to 
obtain a 0.1 % crystal violet solution, and then to obtain the final 0.005 % crystal 
violet solution. 
2. 500 µl of this solution was added on top of the soft agar dishes and incubated for 
30 minutes. 
3. Colony formation was inspected in light microscope and photos were taken. 
2.4  Establishment of transformed cell lines. 
Cell colonies in soft agar were taken out and grown further in monolayer. These 
transformed cells were allowed to replicate for approximately 3 weeks to reach 
populations large enough for further analysis. They were seeded in soft agar a second 
time to make sure that the trait of anchorage independent growth was persistent, and 
that these cells from the colonies were truly clonal. In addition, transformed cells were 
seeded on new 6-well plates.  After grown to confluence and washing tree times in PBS, 
these dishes for RNA analysis were put in -80°C freezer until further processing. Cells 
were also kept for storage at STAMIs liquid nitrogen cell bank for later use.  
Protocol 
1. Colonies were carefully isolated from the soft agar using a 200 μl pipette, while 
looking in the light microscope. 
2. A single colony was mixed with 200 μl fresh medium in a 0.5 ml microcentrifuge 
tube, pipetted up and down to release the cells from soft agar and then seeded 
on 24-well plate. One colony was seeded in each well. Five to ten colonies were 
taken out from each cell line/exposure. 
3. The plate was left in the incubator at 37 °C to allow the cells from the individual 
colonies to fasten and start growing. 
4. After approximately two weeks (when the cell layers in these wells were 
confluent) the cells were passaged and seeded on 6-well plates. 
5. After approximately one week these wells became confluent, the cells were 
passaged, and seeded on 100 mm dishes. 
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6. When the individual populations were large enough, cells were seeded in soft 
agar a second time. Cells were also seeded on new 6-well plates. After grown to 
confluence and washing three times in PBS, these dishes for RNA analysis were 
put in -80 °C freezer until further processing. 
2.5 Proliferation assay 
Proliferation rates were determined during the exposure period and on a subset of the 
transformed cell lines.  
Protocol 
1. Cells were seeded on 6-well plates, 20 000 cells/well (HBEC-12KT), and 10 000 
cells/well (HBEC-2KT) in 4 parallels.  
2. After four days, they were counted, using the Countess- Automated Cell- Counter 
(see 2.1.2) 
3. Proliferation rates were calculated using the following formula:  
-(log c)∙(log n)/3(days)∙log2= Cell divisions/day  
c = number of cells counted the final day.  n = number of cells seeded out. 
(“Working with bacterial yields and growth rates”, available at: 
http://www.mgm.ufl.edu/~gulig/bacgen/handouts/growth.PDF, accessed at 30.05.12) 
2.6 Migration assay 
Increased cellular motility and migration capability is a characteristic associated with 
EMT. In this migration assay, confluent dishes were scraped with a metal spatel to make 
an “open wound” in the cell monolayer. The cells ability to migrate into the open wound 
was then monitored. 
Protocol 
1. Transformed cell lines and non-transformed control were seeded on 100 mm 
dishes at a high density (500 000 cells/well) to obtain confluent dishes. 
2. The next day, a metal spatel was used to create a scratch in the cell monolayer. 
This was done carefully to avoid scratching the plate and thereby making 
migration barriers.  
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3. A spot along this line was marked, and the plates were frequently observed in 
the light microscope and photographed at defined time intervals. 
2.7 DNA methylation assay  
The nucleotide analog decitabine (5-Aza-2`-deoxycytidin) can be used to remove DNA 
methylation. By removing DNA methylation it is possible to get indications whether 
observed gene expression changes are caused by silencing through DNA methylation. 
Decitabine, which cannot be methylated, removes DNA-methylation by its incorporation 
in DNA under replication. It also binds to DNMTs and inhibit their activity. As a result, 
DNA methylation levels will be significantly reduced after a couple of replications with 
the reagent present. Gene expression analysis performed on cells treated with decitibine 
can be compared with gene expression on untreated cells and changes may be indicative 
of DNA methylation. 
Protocol 
1. Day one, transformed cells were seeded on two 6-well plate, 500 000 cells/well.  
2. Day two, cells were exposed to 100, 200 and 500 nM decitabine and DMSO in 
three parallels. 
3. After one week of exposure, cells were washed three times in PBS and stored in 
the   -80 °C freezer until RNA isolation. 
 
 
 
 
 
 
 
40 
 
2.8  Molecular analysis 
Several molecular analyses were performed on the established transformed cell lines 
(Fig 2.3).   
 
Figure 2.3 Outline of molecular analysis. 
2.9 RNA-isolation 
Cells for RNA isolation were taken out from the -80°C freezer. RNA was isolated using 
Isol-RNA Reagent. This is a monophasic solution of phenol and guanidine thiocyanate 
that disrupts and homogenise cells and tissues. It also inhibits RNAses. Isol-RNA isolates 
total RNA and this method is suitable for further analysis of both mRNA and miRNA. 
When chloroform is added to the Isol-RNA homogenate and the solution is centrifuged, 
there will be a separation into three phases: the aqueous (upper) phase that contains 
RNA, the interphase that contains DNA, and the organic (lower) phase that contains 
proteins. RNA is precipitated with isopropanol. 
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Figure 2.4: The separation in three different phases after step 4 in RNA isolation the protocol below. 
Materials: Reagents: 
Twist top vials, with cap  
(Sorensen Bioscience, Inc) 
Isol-RNA  
(5-prime, kat. No. 2302700) 
Centrifuge  
(Eppendorf Centrifuge 5417R) 
Chloroform 
 (Sigma-aldrich) 
Heating block  
(Grant QBT2) 
Isopropanol  
(Merck) 
Vortex  
(Heidolphreax 2000) 
75 % ethanol  
(Kemetyl) 
 DEPC-water 
(see Appendix G) 
 
Protocol: 
1. The 6-well plates were taken from the freezer and placed on ice. Isol-RNA Lysis 
Reagent (1 ml/35 mm well) was added. 
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2. A cell scraper was he used to loosen the cells from the plate. The lysate from 
each well was transferred to a twist top vial and incubated in room temperature 
for five minutes. 
3. 0.2 ml chloroform was added to each vial which was incubated in room 
temperature for 2 to 3 minutes. 
4. The vials where centrifuged at 12000 g, 4 °C, for 15 minutes. 
5. The upper aqueous phase was transferred to a new twist top vial. It was 
important to avoid the contamination from the interphase. 0.5 ml isopropanol 
was added to each vial which was incubated at room temperature for 10 
minutes. 
6. The vials where centrifuged at 12000 g, 4 °C, for 15 minutes. 
7. The supernatant was removed and discarded. 
8. The pellets were washed with 1 ml 75 % ethanol and vortexed. 
9. The vials were centrifuged at 12 000 g, 4 °C, for 15 minutes. 
10. The supernatant was discarded and the pellets were dried for 15 to 20 minutes. 
11. Each pellet was re-suspended in 10 ul nuclease free water and put on ice. 
12. The vials were incubated at 65 °C for 10 minutes, spun down, mixed, and put on 
ice. 
13. The vials were put in the -80 °C freezer for minimum one night. 
14. The RNA samples were incubated at 65 °C for 10 minutes. 
15. RNA was stored in the -80 °C freezer. 
2.9.1 RNA quality and -quantity 
Knowing the concentration of RNA is important to obtain correct dilution (1 ug/uL) that 
should be used in cDNA synthesis. An Eppendorf Biophotometer was used to determine 
nucleic acid quantity and quality. Nucleic acids have absorption maximum at 260 nm. 
RNA concentration was determined by measuring OD (260/280). A A260 absorption of 
1.0 is equivalent to 40.0 ug/ml RNA (and 50.0 μg/ml dsDNA). The optimal value for this 
instrument lies between 0.1 and 1.  
Pure RNA has a 260/280 ratio of 2.0, while pure DNA has a ratio of approximately 1.8. A 
lower ratio may indicate contamination by proteins (aromatic groups) or phenol. 
Aromatic groups have an absorption maximum at 280 nm, while phenols have 
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absorption maximum at 270 nm. Carbohydrates have absorption maximum at 230 nm. A 
260/230 ratio lower than 2.0 indicates possible contamination of sugar, salt or organic 
solutions. 
Materials Reagents 
Biophotometer 
 (Eppendorf) 
TE-buffer  
(see Appendix G) 
Quarts cuvettes 
(QS-Hellma) 
DEPC water 
(see Appendix G) 
0.5 ml microcentrifuge tubes 
 (Trefflab) 
 
 
Protocol 
1. 1 µL RNA sample was mixed with 69 µL TE-buffer in 0.5 ml microcentrifuge tubes to 
obtain a 70x dilution of each sample.  
2. Samples were then transferred to quarts cuvettes. RNA concentration was 
determined by using the biophotometer at 260 nm and 280 nm. 
After the measurements, the samples were diluted, if large enough quantities, to obtain 
1 ug/uL for cDNA synthesis. The samples were stored at -80 °C, until further use. 
2.9.2    RNA quality 
RNA quality was measured on a subset of RNA samples by using Agilent Bioanalyzer RNA 
6000 Nano Kit (No. 5067-1511). Method and results are described in the Appendix C. 
2.10 cDNA Synthesis of mRNA 
Complementary DNA (cDNA) was synthesized from mRNA using the qScript cDNA 
Synthesis Kit (Quanta BioSciences). This kit contains an optimized blend of random and 
oligo(dT) primers. They provide, together with the polyA-tail, a double-stranded 
sequence at the 3' end of the mRNA. cDNA is then synthesized from RNA by reverse 
transcriptase (RT) enzyme.  
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Materials Reagents 
Perkin Elmer Cetus DNA Thermal Cycler 480 
 
qScript cDNA Synthesis kit  
(Quanta BioSciences) 
0.5 ml microcentrifuge-tubes  
(Trefflab) 
TE-buffer  
(see Appendix G) 
Vortex  
(Heidolpreax 2000) 
 
Heating block  
(Grant QBT2) 
 
 
Protocol  
1. Microcentrifuge tubes were marked with sample name and date. 
2. RNA samples (1 ug/ml) were taken out from -80 °C freezer, put on ice, and 
thawed on a heating block at 65 °C. 
3. A master mix was made and mixed with RNA samples in the pre-marked 
microcentrifuge tubes as described in Table 2.3. 
4. The microcentrifuge tubes were incubated in the thermal cycler at the program 
described in table 2.4. 
5. 80 µL TE-buffer was then added each sample. The cDNA was stored at -20 °C. 
Table 2.3: Volume/sample of the reagents for cDNA synthesis. 
Reagents Volume/sample (uL) 
DEPC- water 14 
RNA template (1ug/uL) 1 
qScript  cDNA supermix 4 
qScript RT-enzyme 1 
Total volume 20 
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Table 2.4: Thermal cycle program for cDNA synthesis 
Program step: Temperature, °C: Time, minutes: 
Incubation (primer 
annealing) 
22 5 
cDNA synthesis 42 60 
Incubation (denaturing of 
enzymes) 
85 5 
Cooling 4 5 
2.11  cDNA synthesis from miRNA 
For cDNA synthesis from miRNAs, qScript microRNA cDNA Synthesis Kit (Quanta 
BioSciences) was used. MicroRNAs are not polyadenylated in nature, and consequently 
oligo-dT primers cannot be used directly for cDNA synthesis as in cDNA synthesis of 
mRNA. Therefore, miRNA is polyadenylated in a poly(A) polymerase reaction. qScript 
Reverse Transcriptase and other necessary reagents are subsequently added to convert 
the poly(A) tailed miRNAs into cDNA using an oligo-dT adapter primer.  
Protocol 
Poly(A) Tailing Reaction 
1. Microcentrifuge tubes were marked with sample name and date. 
2. RNA samples (1 ug/ml) were taken out from -80 °C freezer, put on ice, and 
thawed on the heating block at 65 °C. 
3. The following necessary components were added to the premarked 
microcentrifuge tubes, which were then vortexed and centrifuged (see Table 2.5) 
4. The tubes were incubated for 60 minutes at 37 °C followed by 5 minutes at 70 °C 
in the Perkin Elmer Cetus DNA Thermal Cycler 480. 
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Table 2.5:  Volume of reagents for each sample for Poly(A) tailing reaction. 
Reagents Volume/sample (ul) 
DEPC water variable 
RNA template (up to 1 ug RNA) Up to 7  
Poly(A) Tailing buffer 2 
Poly(A) polymerase 1 
Total volume 10 
 
First strand cDNA Synthesis Reaction 
5. Components were mixed in new microcentrifuge tubes as described in Table 2.6, 
vortexed and centrifuged. 
6. The tubes were incubated 20 minutes at 42 °C followed by 5 minutes at 85 °C. 
7. 80 µL TE-buffer (see Appendix G) was then added each sample. The miRNA cDNA 
was stored at -20 °C. 
Table 2.6: Volume of reagents for each sample for First strand cDNA Synthesis Reaction. 
Reagents Volume/sample (uL) 
Poly(a) Tailing reaction (from step 4 above) 10 
microRNA cDNA Reaction mix 9 
qScript Reverse Transcriptase 1 
Total volume 20 
 
2.12 Quantitative real-time PCR (qPCR) 
The polymerase chain reaction (PCR) is a method for amplification of DNA sequences 
using repeated cycles of altering high and low temperatures. Real-time PCR (qPCR) is a 
variant of traditional PCR, and is a much used method for examining gene expression. 
qPCR uses a fluorescent reporter molecule that binds the PCR product and reports its 
presence by fluorescence. In the work for this thesis the fluorescent reporter SYBR green 
was used. As the amount of product increases exponentially during the PCR, the 
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fluorescent signal also increases exponentially, reflecting the amount of product 
produced. Product detection is performed in the exponential phase. A doubling of DNA 
molecules is presumed for each amplification cycle. Based on this, the instrument can 
calculate the concentration of DNA template at the beginning, by using a threshold value 
(Cq value). 
Melting curve analysis 
Melting curve analysis was performed at the end of each qPCR to control for specificity 
of the reaction. Primer dimers and hairpin structures will result in shorter PCR products, 
which will show lower melting temperatures.   
Temperature cycle program 
The PCR reaction consists of a series of repeated temperature cycles. For the work in 
this thesis an initial activation and denaturing step at 95 °C for two minutes was used. At 
this step the DNA polymerase was activated, and DNA became single-stranded. The next 
step was 40 cycles with denaturation of cDNA at 95 °C for 10 seconds followed by a 
primer annealing and extension phase at 60 °C for 30 seconds. The newly synthesized 
DNA strand was template in the next amplification cycle. After 40 cycles one would 
theoretically have X·2⁴⁰ copies if X was the number of copies at starting points and a 
doubling at each cycle was assumed.  
Reference gene 
To compare different samples, it is necessary to have a reference (or normalization) 
gene. This is important because there might be a variation in the quality of cDNA 
synthesized from different samples. This might be due to variation in degradation of the 
RNA samples and to the efficiency of the cDNA synthesis. By including a reference gene, 
this can be compensated for. For the work in this thesis β-actin was used as a reference 
gene. This gene is highly and relatively stably expressed and has turned out to be largely 
unaffected by the different experimental conditions showed here.   
Standard curve 
A standard curve was made as a 4 x dilution series of a mix of samples. Such a dilution 
gives rise to a theoretically Ct distance of two cycles between each dilution. It was 
important that in each PCR cycle, there was a (close to) doubling of product, and that 
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the two cDNA dilution curves were parallel. The gene expression for β-actin between the 
different experiments was examined for eventual biological variation. 
One standard curve was created for each gene in the experiment. In case of a 100 % 
effective PCR reaction the slope of the standard curve will be -3.33. Values between -3.1 
and -3.6 were also accepted as long as the standard curves were parallel because this 
means that the normalization of gene and target gene had similar efficiency. 
2.13 mRNA qPCR 
qPCR of cDNA from mRNA was performed by using two primers in opposite directions of 
the desired gene. The primers were designed to span one or more introns, such that 
amplification of genomic DNA residues in the cDNA sample was avoided. 
Ct values between 20-30 cycles were considered to be optimal for all genes and the 
cDNA samples were accordingly. β-actin is highly expressed, and therefore a cDNA 
amount equivalent to 5 ng RNA input in the cDNA synthesis was used in the qPCR 
reactions. The amount of CYP1A1, CYP1B1, AR, AHR, ERβ and ERα was 100 ng since these 
genes has low expression. 
Concentration of all primers was 25 pmol/μl. For mRNA qPCR PerfeCTa SYBR Green 
FastMix, ROX (Quanta Biosciences) was used. This kit contains AccuFast Taq DNA 
polymerase, SYBR Green I dye, ROX as an internal fluorescence reference, along with 
buffer and stabilizers. 
2.13.1 Primer design and testing 
Primers for FOXA1, FOXA2, GREB, CDH1 and CDH2 were designed by using the NCBI 
primer BLAST. The primers should optimally have a GC-content between the 40-60 % 
and the amplicon should be between 50-150 bases. 
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Table 2.7: Primer sequences for genes that were used in this thesis. 
Gene Primer sequence 5`→3` Reference: 
GREB Forward: 5`-CAAAGAATAACCTGTTGGCCCTGC-3`  
Reverse:  5`-GACATGCCTGCGCTCTCATACTTA-3`                             
Designed for this thesis: 
http://www.ncbi.nlm.nih.gov/tools/
primer-blast/ 
FOXA1 Forward: 5`-GGGGGTTTGTCTGGCATAGC-3` 
Reverse:  5`-GCACTGGGGGAAAGGTTGTG-3` 
Designed for this thesis. 
 
FOXA2 Forward: 5`-GGAGCAGCTACTATGCAGAGCC-3` 
Reverse: 5`-TGTTCATGCCGTTCATCCCCA-3` 
Designed for this thesis. 
 
CDH1 Forward: 5`-ACGCCGAGAGCTACACGTTCA-3` 
Reverse: 5`-TCCTTTGTCGACCGGTGCAATC-3` 
Designed for this thesis. 
 
CDH2  Forward:5`-TCCAACGGGGACTGCACAGAT-3` 
Reverse: 5`-GGCGTTCTTTATCCCGGCGTT-3` 
Designed for this thesis. 
 
Β-actin Forward: 5`-GCGAGAAGATGACCCAG-3` 
Reverse: 5`-GATAGCACAGCCTGGATA-3` 
 (Mollerup, Berge et al. 2006) 
CYP1A1 Forward: 5`-CATCCCCCACAGCACAACA-3` 
Reverse: 5`-CAGGGGTAGGAAACCGTTCA-3` 
(Mollerup, Berge et al. 2006) 
CYP1B1 Forward: 5`-CTGGATTTGGAGAACATACCG-3` 
Reverse: 5`-TGATCCAATTCTGCCTGCAC-3` 
(Mollerup, Berge et al. 2006) 
AHR Forward: 5`-CCCTTGGAAAATCATTGCCA-3` 
Reverse: 5`-GGAGAGGTGCTTCATATGTCGTC-3` 
(Mollerup, Berge et al. 2006) 
ERα Forward: 5`-ACTTGCTCTTGGACAGGAACCA-3’ 
Reverse: 5`-CAAACTCCTCTCCCTGCAGATT-3’    
Designed for this thesis. 
 
ERβ Forward: 5`-GCCGACAAGGAGTTGGTACAC-3’ 
Reverse: 5`AACAGGCTGAGCTCCACAAAG-3` 
Designed for this thesis. 
 
AR Forward: 5’-CCTGGCTTCCGCAACTTACAC-3’ 
Reverse: 5’-GGACTTGTGCATGCGGTACTCA-3’ 
Designed for this thesis. 
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Primers for FOXA1, FOXA2, GREB, CDH1 and CDH2 were tested before gene expression 
analysis was performed. Standard curves were made for each gene. In addition to test if 
the primers would result in optimal PCR slope (slope close to -3.33) these standard 
curves will also give an idea of the expression levels of the genes, and then also how 
much cDNA to use for qPCR. Agarose Gel electrophoresis were performed to that the 
RT-qPCR products from primer testing. This was performed to make sure that it was only 
on products, and that the product had correct length (See Appendix D). 
Protocol 
1. The primers stock solutions were diluted (25 pmol/uL). 
2. Water was filtered sterile through a sterile filter with a 10 ml syringe. 
3. A mastermix was made for each gene, containing primers, PerfeCTa Syber Green 
Fastmix, and sterile-filtered dH₂O.  
4. A 4x dilution of series was made to generate a standard curve.  100 ng was the 
starting point for each series.  
5. 36 uL mastermix was added to PCR tube strips and 10 µL of each of the steps in 
dilution series was added this. 
6. All steps were run in 2 paralells of 20 µL reaction on a 96-well PCR plate. 
7. The 96 well plates were covered by a plastic film. 
8. The PCR plate was centrifugated at 3000 rpm for 30 seconds. 
9. The qPCR file was opened. The PCR plate was put into the machine and the 
program was started. 
2.13.2 mRNA qPCR 
mRNA RT-qPCR was setup by using a pipetting robot. qPCR was performed in 384 well 
plates with reaction volumes of 12 uL. 
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Materials Reagents 
Microcentrifuge tubes 0.5 ml and 1,5 ml 
(Trefflab) 
PerfeCTa Syber Green Fastmix  
Primers 
10 ml one time syringe  
(B. Braun Inject) 
 
Sterile filter 
 (Pall Corporation, Acrodisc Syringe filters) 
 
25 ml centrifuge tubes  
384 wells plate 
(MicroAmp, Applied biosystems) 
 
Centrifuge 
 (Sigma) 
 
Plastic film for 96-wells plate 
 (MicroAmp, Applied biosystems) 
 
Real-Time RT-PCR instrument  
(ABI Prism 7900 HT) 
 
Multichannel pipette 
 (micronic systems) 
 
SDS 2.2 Software 
 (Applied biosystems) 
 
 
Protocol 
1. The pipetting robot (Eppendorf EPmotion 5070) was used to setup qPCR of 
mRNA on 384 well plates. The robot program was made beforehand. 
2. cDNA was pipetted onto a 96 well plate and put into the robot. 
3. A master mix with all contents, except cDNA, was made for each gene in a 1,5 
Eppendorf tube and put into appropriate location in the robot  
4. Water was sterile-filtered and added into the appropriate well in the robot. 
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Table 2.8: Final volumes for each sample in mRNA qPCR. 
Reagents Volume/sample  µl 
(96 well-plate) 
Volume/sample   µl 
 (384 well-plate) 
cDNA 10 10 
dH₂O 12,08 1,5 
PerfeCTa Syber Green 
Fastmix  
 23 uL 12 
Primer forward, 25 pmol/uL 0,46 uL 0,24 
Primer reverse, 25 pmol/uL 0,46 uL 0,24 
Volume in mastermix:  26 14 
Final volume/sample 36 uL 24 
Reaction volume 18 12 
 
2.13.3 miRNA qPCR. 
qPCR detection of miRNAs was performed by using Perferta Universal PCR Primer 
(Quanta Biosciences). This primer is complementary to the adapter sequence added in 
the cDNA synthesis step. The other primer is miRNA specific (this is normally the entire 
mature miRNA sequence)  
Protocol 
1. The pipetting robot (Eppendorf EPmotion 5070) was used to setup qPCR of 
miRNA on 384 well plates. The robot program was made beforehand. 
2. cDNA from miRNA was pipetted onto a 96 well plate and put into the robot. 
3. A master mix with all contents except cDNA was made for each gene in a 1,5 
eppendorf-tube and put into appropriate location in the robot (see table 2.9). 
4. Water was sterile- filtered and added into the appropriate well in the robot. 
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        Table 2.9: Final volumes for each sample in miRNA qPCR.  
Component Volume/sample 
SYBR Green Supermix 12.02  
Perferta microRNA Assay Primer (10 μM) 0.48  
Perferta Universal PCR Primer (10 μM) 0.48 
MicroRNA cDNA 10  
DEPC water 1.02  
Total  volume 24 
 
2.14  Statistical methods  
Statistical analysis was performed by using GrapgPad InStat 3.0 Software (San Diego 
California, USA) p<0.05 was accepted as statistically significant. Comparison of multiple 
groups was performed by using one-way ANOVA followed by post hoc Tukey test.  
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3 Results 
The result section has been divided into two parts. The first part contains results from 
the in vitro transformation of human bronchial epithelial cells. Cellular changes, such 
anchorage independent growth, morphological changes and results from the migration 
assay are described here. Part two describes results from gene expression analysis, 
miRNA expression and results from DNA methylation assay. 
3.1  Optimization of carcinogen dose and exposure frequency. 
In this in vitro transformation assay, it was the intention to mimic the situation occurring 
in the bronchial epithelium of the smoker, as close as possible. This was achieved by 
long-term exposure to tobacco smoke carcinogens.  An important step in the 
optimization of this experiment was therefore to establish doses, as well as exposure 
frequencies and duration of the tobacco smoke carcinogens. Several cytotoxicity tests 
were performed for this purpose. The carcinogen dose should be as high as possible in 
order to provoke cellular changes, but low enough to not be cytotoxic. A cytotoxic dose 
was defined as one leading to more than 30 % reduction in viability. The cytotoxicity 
tests were performed by exposing HBEC cell lines to different doses of tobacco smoke 
carcinogen to establish the dose-response relationships.  
The carcinogens chosen were B[a]P, CSC and MNU. Dose and exposure frequency of 
MNU was based on earlier similar experiments (Damiani, Yingling et al. 2008), and 
cytotoxicity tests were only performed with B[a]P and CSC. In addition, cytotoxicity test 
with medium added serum (FBS) were also performed to investigate if serum itself could 
influence cell behavior.  
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Figure 3.1: Different cytotoxicity test. Columns show the mean value  SD.  A) Serum toxicity tests performed with 
CTB, B) B[a]P cytotoxicity test performed with CTB and C) CSC cytotoxicity test performed with Countess 
Automated CellCounter. No statistical analyses were performed on these results because they were only 
optimization experiments. 
Figure 3.1 shows the results of a subset of the tests performed. Several optimization 
tests were performed (not shown). Based on these and the results presented in Figure 
3.1, two doses of B[a]P and CSC were chosen to use in the transformation assay. One 
low dose that almost did not show any toxicity at all: 0.33 μM B[a]P and 1 μg/ml CSC, 
and one high dose that resulted in approximately 20 % reduction in viability in repeated 
tests: 1 μM B[a]P and 3 μg/ml CSC. Different exposure durations, exposure frequencies 
and cell densities were also tested in these optimization tests. To avoid any cumulative 
toxicity in the 15 weeks transformation assay, exposure for 3 days once a week was 
chosen. Because the effect of carcinogens seemed to be affected by cell density as well 
as dose, it was important that the cell density was not too high. Optimal cell density 
should result in 80 % confluent dishes at the end of the week. Optimal cell density for 
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HBEC-2KT turned out to be 1000 cells/well, while for HBEC-12KT it turned out to be 2000 
cells/well because of different sizes and proliferation rates of the cells.   
All of the three available HBEC cell lines were used in these optimization experiments. 
Earlier results from transformation experiments with HBEC from a donor without lung 
cancer did not result in transformation after exposure to BPDE. Considering the fact that 
the unactivated carcinogen B[a]P was chosen for this experiment, and that this might 
have rendered the cells more refractory to transformation, the two cell lines from 
donors with NSCLC - HBEC-12KT from a female and HBEC-2KT from a male donor- were 
chosen.  
3.2  Transformation  
Before the long-term exposures were initiated in the transformation experiments, it was 
important to have an optimized soft agar assay ready. For the optimization of the soft 
agar assay, two tumor cell lines that have previously been shown to form colonies in soft 
agar were used. The soft agar assay contains a base layer and a cell-containing top layer. 
In the top layer it was important to have an agar concentration as low as possible, but 
still high enough for the agar to gel. The agar was solid in temperatures under 
approximately 35 °C so it was important to work quickly with the agar before it was 
solidifying. As long as the agar was not mixed with the cells, it was kept in water bath at 
40 °C, but when this agar was mixed with cells it should not have a temperature above 
37 °C. Several optimization experiments were performed and as Figure 3.2 shows the 
tumor cell lines A549 formed colonies in soft agar.    
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Figure 3.2: A549 colonies in soft agar and stained with crystal violet.  
In the transformation assay, the two HBEC cell lines were exposed weekly for the 6 
different treatments, including DMSO control. Colony formation in soft agar was tested 
after 9, 12 and 15 weeks of treatment. Cells that acquired the ability of anchorage 
independent growth and thereby formed colonies in soft agar were defined as 
transformed. All treatments were carried out in four parallels that were kept separated 
during the exposure time and these were seeded separately in soft agar. The number of 
parallels that formed colonies for each treatment may be indicative of transformation 
efficiency.  
HBEC-2KT cells exposed to CSC formed colonies in soft agar after 9, 12 and 15 weeks 
exposure. Both doses of CSC and all of the four parallels of each dose resulted in 
colonies. HBEC-2KT cells exposed to B[a]P, MNU and DMSO were also seeded in soft 
agar, but none of these treatments resulted in colony formation. Figure 3.3 shows HBEC-
2KT cells exposed to 1 ug/ml CSC for 12 weeks, after 3 weeks in soft agar. 
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Figure 3.3: HBEC-2KT colonies after 3 weeks in soft agar and staining with crystal violet. Before seeding in soft agar, 
these cells were exposed to 1 ug/ml CSC for 12 weeks.   
HBEC-12KT exposed to CSC, B[a]P and MNU formed colonies in soft agar (Fig. 3.3). 
Transformation efficiency differed among these carcinogens. Only one parallel of each 
dose B[a]P after 9 and 12 weeks formed colonies, and two parallels of each dose after 
15 weeks. After 9 weeks only two parallels of the low dose of CSC formed colonies. Both 
doses of CSC formed colonies after 12 and 15 weeks (3 parallels). Three parallels of 
HBEC-12KT exposed to MNU formed colonies after 9 and 12 weeks, and surprisingly, this 
number was reduced to two after 15 weeks exposure. Exposure to DMSO for 9, 12 and 
15 weeks did not, as expected, result in colony formation. 
 
Figure 3.4: HBEC-12KT colonies after exposure to 1 ug/ml CSC, 0.33 uM B[a]P and 1mM  MNU.  These cells were not 
stained with crystal violet.  
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Figure 3.5 summarizes the results from the transformation and soft agar assays. 
Treatments that lead to colony formation are shown. Exposure to CSC had highest 
transformation efficiency since these exposures lead to transformation in both cell lines, 
while B[a]P exposure showed lowest transformation efficiency with only one, or a few 
parallels, in one cell line, growing as colonies.  
 
Figure 3.5: Treatments that resulted in colony formation in soft agar after 9, 12 and 15 weeks are illustrated. Type 
of carcinogen and the dose is also described:  B[a]P –L = 0.33uM B[a]P ,  B[a]P-H = 1 uM B[a]P, CSC-L= 1ug/ml CSC, 
and CSC-H = 3 ug/ml CSC. The number of the parallels that resulted in colonies is written in parenthesis.  
3.3 Establishment of transformed cell lines 
Several treatments resulted in colonies after 9, 12 and 15 weeks (as previously shown). 
For the establishment of transformed cell lines that could be used in further analyses, 
colonies from soft agar after 12 weeks of carcinogen exposure were chosen. 
These cells were isolated from soft agar, grown further in monolayer, until reaching 
large enough populations for further work, such as migration assay and RNA-isolation 
for molecular analyses. These transformed cell lines were also seeded in soft agar a 
second time to assure that the trait of anchorage independent growth was persistent. 
All these transformed cell lines also formed colonies in soft agar a second time. 
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Isolating cells from soft agar colonies was a difficult process with many critical steps. 
One single colony at the time was taken out from the soft agar and seeded in a single 
well in multi-well dishes to obtain clonal transformed cell lines (all cells originated from 
the same colony). It was the initial intention to isolate four colonies from each 
treatment that resulted in transformation after 12 weeks, but only cells from a subset of 
colonies survived and attached to the dish. Therefore, only 1-2 colonies were 
successfully isolated from each treatment. These transformed cell lines were each given 
its own name that will be referred to in the further analyses (Table 3.1). This table 
specifies the treatment that induced transformation and also which cell line (HBEC-2KT 
or HBEC-12KT) they are derived from. HBEC-2KT derived transformed cell lines are given 
the prename T2-, and HBEC-12KT derived transformed cell lines are given the prename 
T12-. The rest of the name specifies the exposure conditions: T2-CSC-L is transformed 
(T), derived from HBEC-2KT (2) after colony formation in soft agar and 12 weeks 
exposure to CSC, low concentration (CSC-L). In those cases where two transformed cell 
lines have been isolated from separate colonies, but the same cell line and treatment, 
they are given distinct numbers at the end of the name (T12-MNU-1 and T12-MNU-2). 
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Figure3.1: Transformed cell lines and their weekly treatment for 12 weeks. Which cell line (HBEC-2KT or HBEC-12KT) 
they are derived from are specified in the right column. Colonies obtained from the same treatment are given 
distinct numbers (1 and 2) 
Transformed HBEC cell line  Treatment 
T2-CSC-L HBEC-2KT exposed to low dose CSC  
(1 µg/ml). 
T2-CSC-H HBEC-2KT exposed to high dose CSC  
(3 µg/ml). 
T12-CSC-L1 HBEC-12KT exposed to low dose CSC 
(1 µg/ml) isolated from colony 1. 
T12-CSC-L2 HBEC-12KT exposed to low dose CSC  
(1 µg/ml). isolated from colony 2. 
T12-CSC-H HBEC-12KT exposed to high dose CSC  
(3 µg/ml) 
T12-B[a]P-L HBEC-12KT exposed to low dose B[a]P 
(0,33 µM)  
T12- B[a]P-H HBEC-12KT exposed to high dose  
(1 µM B[a]P)  
T12-MNU-1  HBEC-12KT exposed to MNU (1 mM) 
isolated from colony 1. 
T12-MNU-2 HBEC-12KT exposed to MNU (1 mM) 
isolated from colony 1. 
 
3.4 Proliferation assay.  
Proliferation rate was measured during the exposure period on cells exposed to B[a]P 
and DMSO. In addition, proliferation rate was measured on the transformed cell line   
T2-CSC-L. The intention for measuring proliferation rate was to calculate how many 
replications the cells had been through during the exposure period, and to investigate if 
there were any changes in proliferation rate. Divisions/day was calculated and analyzed 
by one-way ANOVA test and Tukey post test. No significant changes in proliferation rates 
were observed during the weekly carcinogen exposures (Fig 3.6). T2-CSC-L did not show 
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any significant change in proliferation rate, when compared to the other HBEC-2KT cells, 
even though it was transformed. A significant difference between the two HBEC cell 
lines was observed, on the contrary, as suspected during the optimization experiments. 
HBEC-2KT has approximately twice as many divisions/day. This means that if HBEC-12KT 
cells have been through approximately 58.8 divisions in the 12 weeks exposure period 
(0.7 divisions /day · 84 days), HBEC-2KT have been through 117 division in the same time 
lapse (1.4 divisions /day · 84 days). This fact should be taken into consideration when 
analyzing results of further experiments, such as for example migration and gene 
expression. 
 
Figure 3.6: Divisions/day on HBEC-2KT and -12KT cells exposed to B[a]P or DMSO and the transformed cell line T2-
CSC-L (black) Columns show the mean value  SD. No differences in proliferation rate between controls (DMSO) 
and exposed cells were statistically significant (One-way ANOVA test with Tukey post-test).  
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3.4  Morphological changes during transformation. 
HBECs originally have a rounded, epithelial shape when grown in monolayer and 
observed in the light microscope. Cellular morphology was inspected several times 
weekly during the carcinogen exposure regimen. The shape of some of the exposed cells 
changed dramatically during this period. The earliest changes were observed in HBEC-
2KT exposed to CSC. These changes appeared after approximately three weeks exposure 
and in both doses of CSC. The cells acquired a more elongated shape, resembling a 
mesenchymal cell type. These were early indications that had activated the regulatory 
developmental program termed Epithelial-to-mesenchymal transition (EMT).  
Similar changes were also observed in HBEC-12KT cell lines exposed to CSC, B[a]P and 
MNU, a few weeks later. Figure 3.7 illustrates the morphological differences between 
transformed cell lines and cells exposed to DMSO. The rounded, epithelial shape, which 
characterized both HBEC-2KT and HBEC-12KT exposed to DMSO is shown in (A) and (E), 
respectively. These photos are taken with low cell-density (A) and high cell-density (E), 
to illustrate that they maintained their rounded, epithelial shape, independent of cell-
density. (B-F) shows transformed cell lines that have been isolated from three weeks in 
soft agar. Even though these morphological changes were observed as early as after 
three weeks of exposure, they maintained this elongated, mesenchymal shape several 
weeks after the removal of carcinogens.  
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Figure 3.7: A) Original epithelial, rounded shape of HBEC-2KT cells. B) Elongated fibroblast-like shape of the 
transformed cell line T2-CSC-L, B and C) shows similar changes in the transformed T12-CSC-L1 and T12-MNU-1 cell 
line, E) HBEC-12KT with normal original shape exposed to DMSO for 12 weeks,  and F) shows the transformed cell 
line T12-B[a]P-L . 
 
In the following, a separate presentation of morphology will be given for HBEC-2KT 
derived transformed cell lines (T2-) and HBEC12-KT derived (T12-). For details about the 
transformed cell lines presented here, and their previous treatment, see Table 3.1. 
Starting with HBEC-2KT, as already described, early changes were observed in cells 
exposed to both doses of CSC. These changes were persistent during the exposure 
period and after removal of CSC. Figure 3.8 shows the original, rounded, epithelial shape 
of DMSO exposed cells (A), and transformed cells with an elongated, mesenchymal 
shape exposed to CSC (C-D). This figure also shows HBEC-2KT exposed to MNU for 12 
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weeks (B). These cells have maintained their epithelial shape similar to the DMSO-
exposed cells. Also, the HBEC-2KT cells exposed to both doses of B[a]P maintained the 
epithelial shape. In conclusion, HBEC-2KT cells that acquired anchorage-independent 
growth and formed colonies in soft agar (transformed) also went through dramatic 
morphological changes, consistent with EMT. Those HBEC-2KT cells that were not 
transformed, on the other hand (DMSO, B[a]P and MNU), maintained their epithelial 
morphology.  
 
Picture 3.8: A and B) HBEC-2KT after exposure to DMSO and MNU, respectively. D and E) The transformed cell lines 
T2-CSC-H and T2-CSC-L.  
Similar morphological changes were observed in most of the HBEC-12KT derived 
transformed cell lines (T12). As shown in Figure 3.7, T12-CSC-L and T12-MNU-1 went 
through a dramatic change in morphology. The same changes were observed for T12-
CSC-L2 and T12-MNU-2, but surprisingly, T12-CSC-H maintained an epithelial 
morphology. So did T12-B[a]P-L (Fig 3.9). In conclusion, not all transformed HBEC-12KT 
changed their morphology, but even though some of the transformed T12- cell lines did 
not have a typically mesenchymal appearance, they may represent intermediate stages 
in EMT.    
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Figure 3.9: A) HBEC-12KT exposed to DMSO with the original, epithelial shape. B- H) Transformed HBEC-12KT (T12-). 
 
In addition to morphological changes, consistent with EMT, overlapping growth was 
observed in several of the transformed cell lines of both HBEC-12KT and HBEC-2KT, 
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indicating loss of contact inhibition (see Figure 3.10). This trait was never observed in 
control cells (DMSO).  
 
Figure 3.10: Transformed cells (T12-MNU-1) with overlapping growth.  
3.5 Migration assay    
Increased cellular motility and migration capability is a characteristic associated with 
EMT. This migration assay is also called wound-healing assay because it is used to 
investigate cells ability to migrate into an experimentally applied open wound in the cell 
layer, and thereby wound-healing. Several of the transformed cell lines had a dramatic 
change in morphology in agreement with EMT, and the migration assay was performed 
to investigate those characteristics further.   
Migration capability was tested on a subset of the transformed cell lines in comparison 
to HBECs exposed to DMSO for 12 weeks. Figure 3.11 shows the results from the 
transformed cell line T2-CSC-L. The figure shows pictures taken just after scratching (1A 
and B), and 24 hour later (2a and b). After 24 hour, the transformed cell line T2-CSC-L 
had completely filled the gap, while DMSO exposed cells had only slightly moved. The 
figure also illustrates, from a different experiment, how the migrating cells fill the open 
wound (3). In conclusion, the tested transformed cell line (T2-CSC-L) had gained an 
increased ability to migrate when compared to DMSO exposed cells.   
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Figure 3.11: 1A and B) T2-CSC-L and DMSO exposed cells, just after scratching, 2A and 2B) Cells 24 hours later, and 
3) migrating T2-CSC-L cells from a different experiment.  
3.6 Gene expression analysis 
RT-qPCR was performed on transformed cell lines (see Table 3.1) in comparison to 
control cells exposed to DMSO (12 weeks). RT-qPCR was performed on genes involved in 
EMT, carcinogen-metabolism and steroid receptor pathways. No changes were observed 
in the expression of CYP1A1, CYP1B1 and AHR. These results are shown in the Appendix 
E.  
Figure 3.12 shows gene expression of the two genes encoding the cadherins CDH1 (E-
cadherin) and CDH2 (N-cadherin). The cadherin-switch, from E-cadherin (CDH1) to N-
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cadherin (CDH2) is a molecular hallmark of EMT. In both T2-cell lines, CDH1 expression 
was strongly reduced, whereas CDH2 expression was strongly induced, in accordance 
with an EMT. CDH1 expression was significantly reduced in five of the seven transformed 
T12- cell lines, while two of these cell lines did not show reduced expression. Four of the 
T12-cell lines had significantly increased expression of CDH2 and there was a tendency 
towards increased expression in the two other cell lines, but these were not significant. 
Overall, there were indications of a cadherin-switch in the T12-cell lines, as well. 
However, in a few of them, there were no clear indications of an abnormal expression of 
the cadherin genes, even though these cell lines were transformed. 
In addition to the cadherin switch, changes in cellular morphology and increased 
migration capability characterize the EMT program. Both of the T2-cell lines had a 
dramatic change in morphology and a highly increased migration capability. In these two 
cell lines there was a strong correlation between the cadherin switch, morphology and 
migration capability. In T12-cell lines, some cell lines did not follow the EMT pattern. 
Both of the T12-B[a]P cell lines and T12-CSC-H maintained their epithelial morphology. 
In T12-B[a]P-H, CDH1 was not downregulated which at least partly may explain the 
epithelial phenotype. In T12-CSC-H and T12-B[a]P-L CDH1 was downregulated, but these 
cell lines still have maintained an epithelial morphology. 
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Figure 3.12: CDH1 and CDH2 gene expression in transformed cell lines. Columns show the mean value  SD. Fold 
changes compared to DMSO are shown over each column. One-way ANOVA test with Tukey post test was 
performed and the following p-values are marked: p<0,05=*, p<0,01=**,  p<0,001=***. A) and B) shows expression 
of CDH1 and C) and D) expression of CDH2 in HBEC-2KT and HBEC-12KT derived cell lines, respectively.  In all cases 
gene expression levels were normalized to the expression of β-actin. 
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Figure 3.13 shows gene expression of AR, ERα and ERβ on the transformed cell lines. The 
expression of AR was significantly upregulated in six of nine transformed cell lines. The 
remaining three also showed a tendency of increased expression, but this was not 
significant. ERα is not expressed in DMSO exposed HBEC-2KT or T2-cell lines. In two T12 
cell lines ERα is significantly upregulated, and in two others there is a tendency, but not 
significant, upregulation of ERα. ERβ was significantly upregulated in four of nine 
transformed cell lines. Three of the remaining cell lines also showed a tendency of 
increased expression, but this was not significant. T2-CSC-L showed a small, but 
significant reduction of ERβ expression. Overall, there are indications of increased 
expression of AR, ERβ and partly also ERα during in vitro transformation. This indicates 
that the steroid receptors may be involved in the transformation process.  
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Figure 3.13: AR, ERα and ERβ gene expression in transformed cell lines. Columns show the mean value  SD. Fold 
changes compare to DMSO are shown over each column. One-way ANOVA test with Tukey post test is performed 
and the following p-values are marked: p<0,05=*, p<0,01=**,  p<0,001=***. A) and B) shows expression of AR, C) 
Expression of ERα and D) and E) expression of ERβ in HBEC-12KT derived cell lines, respectively.  In all cases gene 
expression levels were normalized to the expression of β-actin. 
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Figure 3.14 shows gene expression of FOXA1, FOXA2 and GREB1. FOXA1 was significantly 
downregulated in T2-cell lines, but upregulated in most of the T12-cell lines. Four of 
these changes are significant, while two T12-cell lines show a small and unsignificant 
reduction. FOXA2 is significantly downregulated in T2-cell lines. This gene is moderately 
induced in one cell line (T12-B[a]P), reduced in three (T12-CSC-L) (T12-MNU-1 (T12-
MNU-2), but unaltered in the remaining three.  
GREB1 was expressed in HBEC-2KT exposed to DMSO, but not in T2-cell lines. Therefore 
no statistics is performed on these results, but a downregulation can be assumed. Three 
of the T12-cell lines showed increased expression of GREB1. Overall, FOXA1 showed 
opposite changes in T2- and T12- cell lines. FOXA2 was mostly downregulated with the 
exception of (T12-B[a]P), whereas GREB1 also showed opposite changes in T2- and T12- 
cell lines. The expression of GREB1 appears to largely follow the pattern of FOXA1 
closely, in both T2- and T12-cell lines. 
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Figure 3.14: FOXA1 and FOXA2 gene expression in transformed cell lines. Columns show the mean value  SD. Fold 
changes compared to DMSO are shown over each column. One-way ANOVA test with Tukey post test was 
performed and the following p-values are marked: p<0,05=*, p<0,01=**,  p<0,001=***. A) and B) shows expression 
of FOXA1, C) and D) Expression of FOXA2 and E) and F) Expression of GREB1 in HBEC-2KT and HBEC-12KT derived 
cell lines, respectively.  In all cases gene expression levels were normalized to the expression of β-actin. 
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3.7 DNA methylation assay 
Exposure to the DNA demethylating agent decitabine was performed on T2-CSC-L which 
showed reduced expression of FOXA1 and FOXA2. The result from RT-qPCR on FOXA1 is 
shown in Appendix F. FOXA2 was not expressed after exposure. No effect on the 
decitabine treatment on FOXA1 or expression was observed. RT-qPCR results on FOXA2 
showed no expression this gene. More experiments need to be performed before it is 
possible to conclude from these results since it was only performed once and on one of 
the transformed cell lines. 
3.8 miRNA expression 
The expression of miR-27a, miR-21, and miR-24 was measured by RT-qPCR. miRNA RT-
qPCR results were first analysed by normalizing to β-actin (Fig. 3.15, left column). 
Further analyses showed that the observed changes in gene expression were probably 
mostly due to changes in β-actin. Therefore these results are also presented as Cq-
values, only (Fig 3.15, right column). There were only small changes in the expression of 
these three miRNA both with or without normalization to β-actin. Statistics were eonly 
performed on the Cq-vulues, most of the the changes were not significant. Thus, based 
on these results, changes in miR-27a, miR-21 and miR-24 do not appear to be involved in 
in vitro transformation of HBEC cells. However, as in the case of DNA methylation assay, 
these experiments need to be repeated before we are able to conlude. 
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Figure 3.14: Results from miRNA RT-qPCR. Columns show the mean value  SD. One-way ANOVA test with Tukey 
post test is performed and the following p-values are marked: p<0,05=*, p<0,01=**. Statistics is only performed on 
the Cq-values. 
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4 Discussion 
The aim of this study was to investigate early molecular changes during premalignant 
cell transformation. Steroid receptor pathways have been hypothesized to be involved in 
lung carcinogenesis, possibly by interacting with carcinogen metabolism, and by 
interfering with cellular signaling pathways related to control of cell proliferation (Berge, 
Mollerup et al. 2004). Epithelial-to-mesenchymal transition (EMT) has also recently been 
found to be induced by carcinogens at early stages of lung carcinogenesis (Tellez, Juri et 
al. 2011).  
In vitro studies of early changes during lung carcinogenesis have been restricted by the 
cell lines available, but HBECs were recently immortalized by insertion of Cdk4/hTERT 
(Ramirez, Sheridan et al. 2004). These cells have few genetic alterations and are 
therefore a new valuable tool for studying early changes in vitro. In this study, these cell 
lines were used in an in vitro transformation model to investigate if molecular changes 
involved in steroid receptor pathways, carcinogen metabolism, and EMT was associated 
with premalignant transformation. 
In addition to epidemiological, clinical, and animal studies, in vitro studies are important 
tools for investigating carcinogenesis. There are, of course, weaknesses associated with 
in vitro model systems. The carcinogenic process is extremely complex. An in vitro 
transformation model simplifies parts of this process and one should be careful jumping 
from conclusions found in this system to conclusions about human lung carcinogenesis. 
But, together with knowledge from other approaches, it provides a model that can give 
valuable new insight into lung carcinogenesis.  
Cell lines used for long-term in vitro studies need to have a long-term replicative 
potential. Since primary human bronchial epithelial cell lines have a finite replicative 
potential, they need to be immortalized in order to become long-term replicating 
cultures. Immortalization is often accomplished by introduction of oncogenes or 
silencing of tumor suppressor genes. Many immortalized cell lines therefore do not have 
an intact p53 checkpoint and often become genomically unstable after several passages. 
Genomic instability characterizes later steps of carcinogenesis - cancer progression. In 
vitro models to study early premalignant changes therefore have been restricted by the 
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lack of cell lines with few genetic changes. Since Cdk4/hTERT-immortalized HBECs have 
an intact p53 checkpoint, are genomically stable, and have few genetic alterations, they 
may be more suitable than many other immortalized cell lines as models to study 
premalignant changes (Gazdar, Gao et al. 2010). 
In this in vitro transformation model, the doses of  tobacco carcinogens were intended 
to be low, compared to the doses used in many other in vitro transformation models 
(Veljkovic, Jiricny et al. 2011). This was to mimic the situation occurring in the bronchial 
epithelium of the smoker as close as possible. But still, the carcinogen doses are much 
higher than those occurring in the bronchial epithelium of the smoker. This is because 
cancer development is a long-term process, most often requiring decades of smoking 
exposure to develop. After long-term in vitro exposure, the cells were seeded in soft 
agar to test for colony formation. Anchorage independent growth, evident by colony 
formation in soft agar, has been considered one of the hallmarks of transformation and 
was therefore used in this model to select for transformed cells. HBEC cell lines do not 
form colonies in soft agar at the starting point. Therefore, cells that formed colonies 
were defined as transformed.  
The first goal in this study was to establish an in vitro transformation model and to test if 
HBECs could be transformed by exposure to CSC, B[a]P or MNU. Earlier studies have 
reported CSC-induced transformation with the human bronchial epithelial cell line 
BEAS2B (Veljkovic, Jiricny et al. 2011). Since this cell line is immortalized by using viral 
oncoproteins (Reddel, Ke et al. 1988), and often become spontaneously malignant after 
several passages without any exposures, transformed BEAS2B may be more suitable as 
models to study molecular changes involved in later stages of lung carcinogenesis. 
HBECs have previously been transformed by exposure to MNU and the ultimate 
carcinogen of B[a]P - BPDE (Damiani, Yingling et al. 2008). Since B[a]P needs to be 
bioactivated by carcinogen metabolizing enzymes into BPDE in order to induce DNA 
damage, our model also tested the capacity of HBECs to bioactivate B[a]P sufficiently for 
transformation. The results obtained in this study show for the first time that HBECs 
have the ability to bioactivate B[a]P sufficiently for transformation. This requires the 
presence of CYP enzymes and probably also high induction of these enzymes through 
the AHR (Uppstad, Ovrebo et al. 2010). It should be noted that only one of the tested 
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HBEC cell lines (HBEC-12KT) were transformed by exposure to B[a]P. This may be due to 
experimental conditions, or it may be due to the fact that there is large inter-individual 
variability in the level of CYP1A1 induction (Jacquet, Lambert et al. 1996). 
The next goal was to isolate cells from soft agar colonies that could be established as 
transformed cell lines. These transformed cell lines were then further used as models to 
investigate molecular changes during transformation. Gene expression analyses were 
performed on these transformed cell lines, in comparison to HBEC cell lines exposed to 
DMSO for the same period of time and under the same conditions. Nine different 
transformed cell lines derived from HBEC-2KT and HBEC-12KT were established after 
different treatments and many of them had changed their morphology.  
The morphological shape of the cells in most of the carcinogen treatments changed into 
an elongated, mesenchymal-like shape, while others maintained the original, rounded, 
epithelial shape. These morphological changes turned out to be largely associated with 
transformation. Most of the cells that changed into a mesenchymal-like cell type, also 
acquired the capability of anchorage independent growth, evident by colony formation 
in soft agar. These morphological changes suggested that the transformed cells had 
activated the regulatory developmental program EMT (Kalluri and Weinberg 2009). To 
investigate this hypothesis further, their migration capability was tested. Increased 
motility and migration are hallmark phenotypes of EMT. Those transformed cell lines 
that were tested, showed an increased motility and migration. Downregulation of CDH1 
(encoding E-cadherin) and upregulation of CDH2 (encoding N-cadherin), the so-called 
cadherin switch, has been considered the molecular hallmark of EMT. RT-qPCR 
measurement of gene expression revealed that most of the transformed cells, showed a 
reduced expression of CDH1 and an increased expression of CDH2. These results 
confirmed that EMT was activated in this premalignant in vitro transformation. EMT has 
earlier been associated with later steps of carcinogenesis, but recent studies suggest 
that this program also can be activated during  premalignant stages (Tellez, Juri et al. 
2011). The results obtained in this study support these findings. 
Overlapping growth was also observed in several of the transformed cell lines after 
recovering from soft agar. Overlapping growth is associated with loss of contact 
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inhibition. This has been considered an in vitro surrogate of a mechanism that operates 
in vivo to maintain tissue homeostasis. A protein known as Merlin orchestrates contact-
inhibition via coupling cell surface molecules, such as E-cadherin to their 
transmembrane receptor tyrosine kinases. Merlin thereby strengthens the adhesivity of 
cadherin-mediated cell-to-cell attachments (Hanahan and Weinberg 2011) In conclusion, 
overlapping growth is also a trait associated with transformation. 
Gene expression analyses performed on the nine transformed cell lines showed no 
significant changes in the expression of CYP1A1, CYP1B1 and AHR.  It has previously 
been shown that CYP1A1 and CYP1B1 is of major importance in the bioactivation of 
B[a]P in human lung cell lines, and that exposure to B[a]P induces expression of CYP1A1 
and CYP1B1 (Uppstad, Ovrebo et al. 2010). In this transformation assay, only permanent 
molecular changes were tested. After the exposure period was finished, and the 
carcinogens removed, several weeks passed before the cells were harvested for RNA-
isolation and gene expression measurements. Considering the rapid turnover of CYP1A1 
mRNA (McLemore, Adelberg et al. 1990), this may explain why no significant changes 
were observed in these genes.  
Steroids are involved in carcinogenesis through several mechanisms. Estrogen can 
stimulate cell signaling and proliferation in the breast via ER pathways (Yager and 
Davidson 2006), and androgens enhance DNA damage and oxidative stress during 
hepatocarcinogenesis (Ma, Hsu et al. 2008). Epidemiological and molecular studies 
indicate that females may be more susceptible than males to tobacco smoke 
carcinogens (Zang and Wynder 1996; Haugen 2002; Siegfried, Hershberger et al. 2009). 
It has therefore been suggested that steroid receptor pathways are involved in lung 
carcinogenesis, possibly through an interaction with carcinogen metabolism. There is 
large inter-individual variability in the level of CYP1A1 induction, and high CYP1A1 
induction has been considered a risk factor for lung cancer (Jacquet, Lambert et al. 
1996). Previous studies have shown a higher level of CYP1A1 gene expression and PAH-
related DNA adducts among female lung cancer patients (Mollerup, Ryberg et al. 1999). 
In vitro studies suggest complex interactions between ER and AHR pathways (Thomsen, 
Wang et al. 1994). Such interactions may be involved in explaining the higher level of 
CYP1A1 mRNA among female lung cancer patients. In this study, we wanted to test if 
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changes in the expression of steroid receptors were associated with the carcinogen 
induced transformation. Our results show that AR, ERβ, and partly also ERα were 
upregulated in the transformed cell lines. In conclusion, upregulation of steroid 
receptors may be associated with carcinogen induced transformation. 
The transcription factors FOXA1 and FOXA2 are involved in regulating steroid receptor 
activity. Because we have an interest in steroid receptor pathways in relation to 
carcinogen metabolism gene expression of these transcription factors was also 
measured. FOXA factors may be a link between steroid receptors and carcinogen 
metabolism. In liver cancer, genes regulated by FOXA factors and steroid receptors 
clustered in the pathways controlling carcinogen metabolism (Li, Tuteja et al. 2012). 
Besides, these transcription factors have recently been found to be involved in several 
cancers. In human breast and prostate cancer cell lines, the recruitment of ERα or AR, 
receptively, depends on FOXA1 (Carroll, Liu et al. 2005). FOXA1 and FOXA2 are also 
thought to be important for sex differences in liver  cancer, where estrogen has a 
protective effect, and androgen a deleterious effect (Kongsuwan, Knox et al.). Little is 
known about the FOXA transcription factors in lung cancer. We found that changes in 
the expression of FOXA1 and FOXA2 were associated with carcinogen induced 
transformation.  FOXA1 was found to be upregulated in HBEC-12KT derived cell lines. 
This is in accordance with one earlier study performed on FOXA1 and lung cancer in 
which it was found that FOXA1 was overexpressed and amplified in lung 
adenocarcinomas (Lin, Miller et al. 2002 . In HBEC-2KT derived cell lines, on the contrary, 
FOXA1 was downregulated. FOXA2 was mostly downregulated in the transformed cell 
lines. This is in support of a recent study, where it was found that FOXA2 was frequently 
downregulated in lung cancer.  
The FOXA factors may also form a possible link between steroid receptors pathways and 
EMT. FOXA2 has been found to act as a suppressor of EMT in human lung cancers. 
Abundance of FOXA2 has been shown to be positively correlated with an epithelial 
phenotype, and negatively correlated with the mesenchymal phenotype (Tang, Shu et al. 
2011). Consistently, knockdown of FOXA2 promoted EMT in lung cancer cells, whereas 
overexpression of FOXA2 reduced EMT. Also, in pancreatic cancer, loss of FOXA1/2 is 
essential for the EMT. In pancreatic ductal adenocarcinoma cell lines, forced inhibition of 
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FOXA1/2 has been shown to be sufficient to induce EMT (Song, Washington et al. 2010). 
E-cadherin has been called the “gatekeeper of the epithelial phenotype” and it is shown 
that FOXA1/2 overexpression can overcome several repressive signals of CDH1 (E-
cadherin gene) expression. Our results from gene expression analyses performed on 
transformed cell lines show that both FOXA2 expression and CDH1 expression was 
downregulated, in comparison to untransformed DMSO-exposed cells. The exception 
was T12-B[a]P-H which showed an increased expression of FOXA2. Interestingly, this 
transformed cell line is the only cell line that does not show any tendency of 
downregulation of CDH1. This support the hypothesis that increased FOXA2 expression 
may overcome other suppressive mechanisms of E-cadherin. Overall, the gene 
expression analyses and morphological observations all show an association between a 
change in morphology, reduced FOXA2 expression and reduced E-cadherin expression.  
Another gene that may be involved in steroid receptor activity is GREB1. GREB1 is an 
ERα target gene and is critically involved in the estrogen induced growth of breast 
cancer cells, (Chand, Wijayakumara et al. 2012). Little is known about GREB1 in lung 
cancer. Our results show that GREB1 was upregulated during carcinogen induced 
transformation of HBECs. Interestingly, the expression of GREB1 in the different 
transformed cell lines seem to follow the expression of FOXA1. In HBEC-12KT derived 
cell lines also ERβ also follows this pattern. The fact that GREB1 is significantly 
upregulated in several of the transformed cell lines indicates that this gene may also be 
involved in lung cancer, but its role needs to be investigated further. 
Epigenetic mechanisms are highly involved in lung carcinogenesis and also in several of 
the processes described in this study. The mechanism of downregulation of FOXA2 in 
lung cancer has been found to primarily be promoter hypermethylation (Basseres, D'Alò 
et al.). DNA-methylation assay followed by gene expression analyses performed in our 
study did not support that promoter hypermethylation was responsible for 
downregulation of FOXA1, but these experiments needs to be repeated. A recent study 
found that miR-200 familiy and miR205 was associated with EMT during carcinogen 
induced transformation of human lung epithelial cells (Tellez, Juri et al. 2011). MiR-21 is 
one of the most studied miRNAs in cancers, and is overexpressed in the most solid 
tumors, promoting progression and metastasis (Tian, Tu et al. 2012). MiR-21 expression 
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was tested on the transformed cell lines in this study. Only small changes were observed 
in the expression of miR-21, or the other miRNA that was tested (miR-24 and miR-27a) 
and mostly not significant. 
In conclusion, an in vitro transformation model was successfully established in this 
study. It was shown that HBECs are capable of bioactivating indirect-acting carcinogens, 
such as B[a]P, sufficiently for transformation. Exposure to other tobacco smoke 
carcinogens also resulted in transformation. By using these transformed cell lines in 
further studies we found that changes in the expression of steroid receptor pathway 
members, including FOXA1/2, changed during carcinogen induced transformation. An 
upregulation of steroid receptors was observed. This indicates that steroid receptors 
pathways may be involved in lung carcinogenesis. In addition, an activation of EMT was 
observed during this premalignant transformation, and a downregulation of FOXA2. 
These results also lend support to the hypothesis that FOXA2 may also be involved in 
regulating EMT.   
For further work, the transformed cell lines from this study can be tested for their 
tumorigenic potential by subcutaneous injection in nude mice. Cells were also harvested 
after 6, 9 ,12 and 15 weeks of exposure for protein and DNA analyses, and cDNA is 
already made from cells exposed to carcinogens for 6, 9 ,12 and 15 weeks. It would be 
interesting to test gene expression of steroid receptors on HBEC-2KT cells exposed to 
B[a]P that did not become transformed. Are their steroid receptors also upregulated?  
In addition, the establishment of an in vitro transformation model can be valuable also 
for testing other chemicals and investigate changes in morphology, EMT and gene 
expression after exposure and possibly transformation. Especially, a similar in vitro 
transformation of HBECs, but with the presence of steroid receptors and FOXA factor 
inhibitors would be interesting. If the presence of inhibitors of steroid receptor 
pathways could inhibit transformation, this would be very interesting for therapeutic 
purposes. 
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A. General cell culture work 
Thawing cells 
Materials 
- Centrifuge (Eppendorf 5702) 
- Light microscope (Nikon Diaphoto) 
Reagents 
- Growth medium 
- DNAse 
- Trypsin 
Protocol 
1. An ampoule was taken from the nitrogen tank and thawed in water bath (37 °C) 
2. The cells were transferred to a centrifuge tube and 5 ml media was slowly added. 
3. The tube was centrifuged (1000 rpm, 4 minutes) 
4. The supernatant was removed and the pellet was re-suspended in 3 ml medium. 
5. The cell suspension was pipette into a petridish (100mm) already containing 5 ml 
of medium (8 ml in total) 
6. The petridish was incubated at 37 °C 
Passaging cells 
Protocol 
1. The media over the cells was removed. 
2. The cells were washed twice in 8 ml PBS. 
3. 1 ml trypsin was added to the dish, and the cells were incubated for five minutes 
in incubator locker until the cells had loosened. This was checked in the 
microscope. 
4. 5 ml media was added and pipette up and down to separate cells, and the cells 
were transferred to a centrifuge tube and centrifugated (1000 rpm, 4 minutes) 
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5. The supernatant was removed and treated with DNAse to facilitate separating 
the cells.  
6. The pellet was re-suspended in medium. Amount of medium used depended on 
the desired dilution of the cells. 
7. Cell suspension (1 ml) was pipetted to a new petridish added 7 ml medium (8 ml 
in total) 
8. Cells were incubated in 37 °C  
Freezing cells 
Protocol 
1. The protocol for passaging of cells was followed to point number 5. 
2. The cell pellet was re-suspended in 500 µL freezing medium (AF solution) and 
transferred to a twist top vial. 
3. 500 µL DMSO freezing media solution for cell culture storage was added and the 
suspension was mixed well. 
4. The vial was put in an insulated box and placed at -80°C for 4 to 6 hours and then 
placed in STAMIs liquid nitrogen cell bank for a long-term storage. 
Collagen coating of petridishes or cell culture plates 
Protocol 
1. Purified collagen solution for cell culture was diluted in PBS to a total 
concentration of 0.03 mg/ml 
2. 3 ml was added 100 mm dishes, 1 ml to each well in 24-wells plates, 500 µL to 
24-well plates and 100 µL to 96-well plates so that the dishes/plates were 
completely covered. 
3. The dishes/plates were incubated at room temperature in the LAF bench for 2 
hours. 
4. The collagen solution was removed and the dishes were washed with PBS. 
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B.  CellTiter Blue assay – Fluorescence and number of 
cells 
This diagram shows the relationship between number of cell and fluorescence.   
 
 
Figure B: Diagram showing the relationship between number of cells and fluorescence. Columns show the mean 
value  SD.  
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C.          RNA quality - Agilent Bioanalyzer 
Agilent RNA kits are designed for the analysis of total RNA and mRNA samples. 
Materials 
 
Reagents 
 
RNA nano chip 
electrode cleaners 
Agilent RNA 6000 Ladder  
RNA Nano Dye Concentrate 
Agilent 2100 Bioanalyzer instrument Agilent RNA 6000 Nano Marker 
Centrifuge  
(Eppendorf Centrifuge 5417R) 
Agilent RNA 6000 Nano Gel Matrix 
 
Heating block  
(Grant QBT2) 
Spin filters   
 
Micro centrifuge tubes  
(Trefflab) 
DEPC water 
 
RNAseZAP (Ambion, Inc. cat.no.9780)  
 
Protocol 
1. A 200 ng/uL solution was made of all RNA samples. All RNA samples were 
denatured at 70°C before use.  
2. The gel was prepared 
a. 550 µL of RNA 6000 Nano gel matrix was pipetted into a spin filter. 
b. This was centrifugated at 1500 g for 10 minutes at room temperature. 
c. 65 µL filtered gel was aliquoted into 0.5 ml micro centrifuge tubes 
3. The Gel-Dye Mix was prepared 
a. The RNA 6000 Nano dye concentrate was allowed to equilibrate to room 
temperature for 30 minutes. 
b. RNA 6000 Nano dye concentrate was vortexed for 10 seconds, spinned down, 
and added 1 uL of dye into a 65 µL of filtered gel. 
94 
 
c. The solution was vortexed well. The tube was spinned at 13000 g for 10 
minutes at room temperature. 
4. The Gel-Dye Mix was loaded 
a. A new RNA 6000 Nano chip was put on the chip priming station. 
b. 9.0 µL of gel-dye mix was pipetted in the well marked (G) 
c. The chip priming station was closed after it was made sure that the plunger 
was positioned at the one ml position. 
d. The plunger was pressed until it was held by the chip 
e. After 30 seconds the chip was released 
f. After 5 seconds, the plunger was slowly pulled back to 1 ml position. 
g. The chip priming station was opened, and 9.0 µL of gel-dye mix was pipetted 
in the wells marked (G). 
h. The remaining gel dye mix was discarded. 
5. The Agilent RNA 6000 Nano Marker was loaded 
a. 5 µL of the RNA 6000 Nano Marker was pipetted in all 12 sample wells and in 
the well marked for ladder. 
6. The ladder and samples were loaded 
a. 1 uL of prepared ladder was pipette in the well marked ladder. 
b. 1 uL of sample was pipetted in each of the 12 sample wells. 1 µL of RNA 6000 
Nano Marker was pipetted in each unused sample well. 
c. The chip was put horizontally in the adapter of the IKA vortexer and vortexed 
for 1 minute at 2400 rpm. 
d. The chip was runned within 5 minutes in the Agilent 2100 bioanalyzer. 
 
Figure C: 1a and 1b) Shows the results from HBEC cells treated with 1 uM B[a]P. 
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D. Agarose gel electrophoresis 
Agarose gel electrophoresis can be used to separate DNA molecules.  This was used to 
test that the primers had correct length and that there was only one product. A gel 
concentration of 3 % (NuSieve gel) was used at 120 V for 90 minutes.  Figure D shows 
the results from CDH1, CDH2, FOXA1 and GREB1. 
 
Figure D: Result from Agarose gel electrophoresis. 
 
 
 
 
 
 
 
96 
 
E. RT-qPCR results of CYP1A1, CYP1B1 and AHR. 
 
Figure E: Columns show the mean value  SD. Results from qPCR on four transformed cell lines. HBEC-12KT derived 
cell lines are in grey, and HBEC-2KT derived cells are in black. 
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F. DNA methylation assay 
 
Figure F: Columns show the mean value  SD.  
 
G. Solutions 
 
AF- medium (Antibiotic freezing medium) 
- 76% L-15 medium 
- 2% 1M HEPES 
- 2% PS 
- 20% FBS 
The solution was sterilefiltered and stored at -4°C. 
DEPC water 
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Diethylpyrocarbonate (DEPC) was added distilled water (ddH₂O) to obtain a 0.1% DEPC 
water solution. 
DMSO (dimethylsulfoxide) for cell culture storage 
- 50 % L-15 medium 
- 2 % 1M HEPES 
- 8 % DMSO 
- 40 % FBS 
The solution was sterile-filtered and stored at -4 °C. 
DNAse (4mg/ml) 
- 4 g DNAse 
- 87.66 mg NaCl 
- 5.06 mg MgSO₄ 
- H₂O to 1 ml 
The solution was stored at -4°C. 
Ethanol in DEPC water (75%) 
12.5 DEPC water, absolute ethanol to 50 ml. The solution was stored in the fridge. 
Fetal Bovine Serum (FBS) 
The serum was heat inactivated at 56 °C for 45 minutes and stored at -4 °C. 
HEPES 
- 238.3 g HEPES 
- 1 ml 0.12% phenol red in 1 L ddH₂O, pH 7.3 
Phenol red 
- 125 g phenol red 
- 360 µL 1M NaOH 
- 100 ml H₂O 
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Phosphate buffered saline (PBS) 
- 7.07 g NaCl 
- 0.20 g KCl 
- 1.94 g NaHPO₄ ∙ H₂O 
- H₂O to 1 L. 
 
 
 
 
  
 
 
